Curriculum vitae

Name:	Lesley Probert
Nationality:	British
Address:	Laboratory of Molecular Genetics, Hellenic Pasteur Institute, 127 Vassilissis Sophias Ave., 115 21 Athens, Greece.
Tel:	+30 210 6478866
e-mail:	lesley.probert@gmail.com; lesley@pasteur.gr
website:	www.pasteur.gr

DEGREES

B.Sc	**Biology;** First class honours. University of London
Ph.D	**Medicine;** Thesis: Electron Immunocytochemical Study of Peripheral Peptidergic Nervous System in Normal Tissues & Inflammatory Bowel Disease. RPMS, University of London (supervisor Dame JM Polak)

DISTINCTIONS

1972	Girls Public Day School Trust, UK (GPDST) – full mid and high school scholarship awards & 5th Form School Prize
1979	H. Munro Fox Prize in Biology, Bedford College Prize for best Degree in Life Sciences in 1979
1982	EMBO two-week training fellowship for practical course in Cryoultramicrotomy (EMBL, Heidelberg, Germany)
1988	European Science Foundation short-term fellowship, Laboratory of Molecular Biology (LMB), University of Cambridge, UK
1988	Scientific Consultant to Genentech, San Francisco, USA
1989	European Science Foundation short-term fellowship, Laboratory of Molecular Biology (LMB), University of Cambridge, UK
1990	Scientific Consultant to Celltech, Slough, UK
1997	Multiple Sclerosis Society of Great Britain & Northern Ireland, Best Presentation Prize
1997	Scientific Consultant to Amgen, Boulder, USA
1998	Investigator Award -18th European Workshop Rheumatology Research, Athens
1998-2002	Scientific Consultant to Boehringer Ingelheim Int. GmbH, Vienna, Austria
2008-2014	International Society of Neuroimmunology (ISNI) -International Advisory Board (elected).
2002-present	European School of Neuroimmunology (ESNI) - Member of scientific committee (elected), individual course organizing committees and course instructor.
2012-present	Hellenic Academy of Neuroimmunology (HELANI) – founding member and vice president.
2018-	Secretary/Treasurer International Society for Neuroimmunology (ISNI)

PROFESSIONAL CAREER

2014- present	**Head of Department of Immunology**, HPI, Athens, Greece
2006- present	**Head of Laboratory of Molecular Genetics**, HPI, Athens, Greece (Researcher A level)
2000- 2006	**Head of Laboratory of Molecular Genetics**, HPI, Athens, Greece (Researcher B level)
2000-2006	**Scientific Director of the Experimental Animal Unit**, HPI, Athens, Greece
2000-2003	**Head of Department of Molecular Genetics & Immunology**, HPI, Athens, Greece
1994- 2000	**Researcher C level,** Laboratory of Molecular Genetics, HPI, Athens, Greece
1990- 1994	**Postdoctoral Fellow,** Laboratory of Molecular Genetics, HPI, Athens, Greece
1987-1990	**Visiting Research Fellow,** Medical Research Council (MRC), Molecular Neurobiology Unit, Laboratory of Molecular Biology (LMB), University of Cambridge, UK
1983-1985	**Wellcome Trust Postdoctoral Fellow,** Laboratory of Neurochemistry, Department of Biochemistry, Imperial College of Science, Technology & Medicine, University of London, UK
1983	**Senior Research Officer,** Department of Histochemistry, Royal Postgraduate Medical School (RPMS), Hammersmith Hospital, University of London, UK
1982	**Research Officer,** Department of Histochemistry, RPMS, Hammersmith Hospital, University of London, UK
1979-1982	**Medical Research Council PhD Scholar,** Department of Histochemistry, RPMS, Hammersmith Hospital, University of London, UK
1976-1979	**Shrewsbury Council BSc Scholar,** Bedford College, University of London, UK

PROFESSIONAL SOCIETIES & ORGANIZATIONS

2002	European School of Neuroimmunology (ESNI) – member of scientific committee, member of course organizing committee, instructor, representative of Greece until present.
2008	International Society of Neuroimmunology (ISNI) –elected member of International Advisory Board (two 3-year terms)
2007	Member of Society for Neuroscience (SfN)
2008	Member of Hellenic Society for Neurosciences
2012	Vice-President & founding member of Hellenic Academy of Neuroimmunology
2018-	Treasurer-Secretary International Society of Neuroimmunology (ISNI)

HOBBIES

Athletics	Greece race for the cure (breast cancer), 5 Km, September 25, 2016 UnderArmourRun, Kifisia City Challenge, 11 Km, October 2, 2016 People Run2, 8 Km, October 16, 2016 Syros Run, 10 Km, May 26, 2018 Athens Authentic Marathon, 10 Km, 2018

FUNDING

2018-2021 **Greek General Secretariat of Science and Technology-** Research, Development & Innovation Project entitled **"**Development of an advanced humanized animal model for multiple sclerosis: application for pre-clinical study of new therapies". Coordinator M. Androutsou, Principal Investigator L. Probert. Duration 36 months (2018 – 2021). Total budget 834.900,71 € (2 partners and 1 company), Laboratory of Molecular Genetics 397.680,71 €.

2017-2018 **MS Society, UK-** Grant entitled "Is cellular senescence responsible for disability progression in progressive multiple sclerosis? Principal Investigator R Nicholas, Imperial College, London, UK. Participant L. Probert. Duration 9 months (October 2017-June 2018). Budget 40.000,00 UKP.

2016-2019 **Multiple Sclerosis Trials Collaboration, UK-** Grant entitled "The role of cellular ageing in disability progression in multiple sclerosis". Co-Principal Investigators L. Probert & D Papadopoulos. Duration 36 months (February 2016-February 2019). Budget 80.400,00 UKP (1 partner).

2014-2015 **Greek General Secretariat of Science and Technology-** Bilateral R&T Collaborations - Greece-Israel project entitled "A novel combined approach for the immunotherapy of multiple sclerosis". Coordinator J. Matsoukas, University of Patras, Greece. Duration 17 months (2014- 2015). Total budget 384.000,00 € (3 partners and 2 companies), Laboratory of Molecular Genetics 40.000,00 €.

2011-2015 **Greek General Secretariat of Science and Technology-** Cooperation Project entitled **"**Pre-clinical and Toxicology Evaluation of Immunodominant Myelin Peptides/Mimetics Conjugated with Mannan towards Clinical Phase I-II Studies: A Potential Therapeutic Vaccine Drug in the Treatment of Multiple Sclerosis (MS)". Coordinator J. Matsoukas, University of Patras, Greece. Duration 36 months (2011 – 2014). Total budget 2.250.000,00 € (3 partners and 2 companies), Laboratory of Molecular Genetics 586.000,00 €.

2010-2013 **EC Seventh Framework Programme-** Regional Potential project REGPOT-2010-1 /246083 entitled "Develompment of a Center of Excellence in Neurosignalling" acronym NeuroSign. Coordinator S. Tzartos, Hellenic Pasteur Institute, Athens, Greece. Duration 36 months (2010-2013). Budget for 3 HPI labs (S. Tzartos, R. Matsa, L. Probert) 1.869.910,00 €

2005-2010 **EC Sixth Framework Programme-** Life Sciences, Genomics and Biotechnology for Health project LSHM-CT-2005-018637 entitiled "Neuroprotective strategies for multiple sclerosis" acronym NeuroproMiSe. Coordinator F. Aloisi, . Duration 60 months (2005-2010). Total EC contribution 11.399.997,43 € (20 partners), Laboratory of Molecular Genetics 631.293,89 €.

2005-2009 **Greek General Secretariat of Science and Technology Third Community Support Programme 2000-2006**. ΠΕΝΕΔ 03 ΕΔ298 project entitled "Investigation of the immune-regulatory role of Core and the recently identified Core+1 proteins of the Hepatitis C Virus: Application of cutting-edge technologies-prospects for therapy" Coordinator P. Mavromara, Hellenic Pasteur Institute, Athens, Greece. PhD studentship for Maria Evangelidou, BSc, MSc. Duration 36 months (2006-2009). Total budget 211.500,00 € (3 partners), Laboratory of Molecular Genetics 62.165,00 €.

2005-2009 **Greek General Secretariat of Science and Technology Third Community Support Programme 2000-2006**. ΠΕΝΕΔ 03 ΕΔ827 project entitled "Design, synthesis and biological evaluation of MBP analogues for immunotherapy in multiple sclerosis" Coordinator J. Matsoukas, University of Patras, Greece. PhD studentship for Mary Emmanouil, BSc, MSc. Duration 36 months (2006-2009).

Total budget 180.000,00 € (6 partners), Laboratory of Molecular Genetics 42.908,00 €.

2006-2011 **European Cooperation in the Field of Scientific and Technical Research:** COST Action BM0603: "Inflammation in Brain Disease" (NEURINFNET). Coordinator T Owens, University of Southern Denmark, Odense, Denmark. Duration 48 months (2006-2011). Scientific missions between partner countries are funded.

2005-2010 **European Cooperation in the Field of Scientific and Technical Research:** COST Action B30: "Neural Regeneration and Plasticity" (NEREPLAS). Coordinator J-M Delgado-Garcia, University Pablo de Olavide, Seville, Spain. Duration 48 months (2005-2010). Scientific missions between partner countries are funded.

2003-2006 **Greek General Secretariat of Science and Technology Third Community Support Programme 2000-2006**. Bilateral R&T Collaborations - Greece-France project entitled "Evaluation of the role of angiopoietin-1 as a neuroprotective mediator of the blood-brain barrier in cerebral ischaemia and experimental autoimmune encephalomyelitis". Coordinator L. Probert. Duration 24 months (2004- 2006). Budget for Greek contribution 25.000,00 €.

2004-2006 **Hellenic Pasteur Institute Research Grant** - Project entitled "Study of the role of core/core+1 proteins of hepatitis C in hepatic carcinoma using transgenic mice". Coordinator P. Mavromara, Laboratory of Molecular Virology, Hellenic Pasteur Institute, Athens, Greece. Duration 24 months (2004-2006). Total budget 25.000,00 € (2 partners).

2003-2006 **Greek General Secretariat of Science and Technology Third Community Support Programme 2000-2006**. Project YB/76 entitled "New Directions in Immunotherapy of Multiple Sclerosis using Novel Cyclic Analogues of the 87-99 Epitope of Myelin Basic Protein alone or conjugated with Mannan". Coordinator J. Matsoukas, University of Patras, Greece. Duration 40 months (2003- 2006). Total budget 320.000,00 € (8 partners), Laboratory of Molecular Genetics 36.150,00 € .

2003-2005 **Greek General Secretariat of Science and Technology Third Community Support Programme** EPAN 2000-2006. Bilateral R&T Collaborations - Greece-USA project entitled "Development of a Neural Network for Brain Inflammatory Diseases". Coordinator L. Probert. Duartion 24 months (2003- 2005). Budget for Greek contribution 64.850,00 €.

2002-2004 **Greek General Secretariat of Science and Technology Third Community Support Programme** EPAN 2000-2006. Bilateral R&T Collaborations - Greece-France project entitled "Evaluation of the neuroprotective properties of FLIP during experimental cerebral ischaemia using transgenic technology". Principal Investigator L. Probert, Ph.D. Duration 36 months (2002- 2004). Budget for Greek contribution 24.652,00 €.

2000-2002 **Greek General Secretariat of Science and Technology Third Community Support Programme** EPAN 2000-2006. Bilateral R&T Collaborations - Greece-China project entitled "Role of FLIP in the regulation of experimental autoimmune encephalomyelitis in transgenic animals". Coordinator L. Probert. Duration 24 months (2000-2002). Budget for Greek contribution 15.250,00 €.

2000-2002 **Hellenic Pasteur Institute Research Grant** - Project entitled "Roles of cellular FLIP and viral NS5A as modulators of death receptor-mediated neuronal apoptosis *in vivo*". Coordinator L. Probert. Duration 24 months (2000-2002). Total budget: 14.674,00 € (2 partners).

1999-2001 **Hellenic Pasteur Institute Research Grant** - Project entitled "Biological function of selected viral proteins from hepatitis C". Coordinator U. Georgopoulou, Laboratory of Molecular Virology, Hellenic Pasteur Institute,

Athens, Greece. Duration 24 months (1999-2001). Total budget: 14.674,00 € (2 partners).

2000-2002 **Greek General Secretariat of Science and Technology EPET II Programme -** PENED 99 project 99ED349 entitled “Design, synthesis and biological action of peptide mimetics of Myelin Basic Protein that antagonize the development of experimental autoimmune encephalomyelitis (EAE) in laboratory animals, for the therapy of multiple sclerosis”. Coordinator A. Mouzaki, University of Patras, Greece. PhD studentship for Era Taoufik, BSc, MSc. Duration 36 months (2000-2002). Total budget 146.735,00 € (3 partners).

1998-2002 **Greek General Secretariat of Science and Technology EPET II Programme-** EKBAN project 115 entitled “Peptide Mimetics-The New Generation of Therapeutics”. Co-ordinator J. Matsoukas, University of Patras, Greece. Duration 36 months (1998-2002). Total budget 821,717 Euro (10 partners), Laboratory of Molecular Genetics 12.000,00 €.

1996-1999 **EU Fourth Framework Programme 1994-1998.** BIOTECH 2 project BIO4CT-960174 entitled “Modeling human neuroinflammatory and demyelinating disease in transgenic and mutant animals”. Coordinator L. Probert. Duration 36 months (1996-1999). Total EC contribution 1,315,000 € (9 partners); Laboratory of Molecular Genetics 300.000,00 €.

1996-1997 **Greek General Secretariat of Science and Technology -** PENED 1995 Research Project entitled "Generation and Characterisation of Transgenic Models of Human Neuroinflammatory Disease in Transgenic Mice". Coordinator L. Probert. PhD studentship for George Kassiotis, BSc. Duration 24 months (1996-1997). Total budget 23.478,00 €.

2000-2006 **Bioindustrial Programmes** with national and international pharmaceutical companies, or collaboration with academic community for a) pre-clinical testing of pharmaceuticals in models of chronic immune diseases, b) licensing of transgenic mice to for-profit organizations, c) development of new transgenic lines, chimaeric mouse systems.

TEACHING ACTIVITY

ORGANIZATION OF INTERNATIONAL MEETINGS

2018 **Athens International Master's Programme in Neuroscience** - Neuroimmunology course organizer, established 2017.

2013 **Twenty-sixth Meeting of the Hellenic Neuroscience Society jointly with FP7 REGPOT NEUROSIGN**, "Understanding Brain Function to Treat Dysfunction", Evgenidio Foundation, Athens, Greece. Symposium organizer and chairperson, "Inflammation and degeneration in the nervous system", speakers Prof. Trevor Owens (University of Southern Denmark, Odense, Denmark), Ms Maria Karamita (Hellenic Pasteur Institute, Athens, Greece), Prof. Malu Tansey (Emory University, Atlanta, USA), Spiros Georgopoulos (Biomedical Research Foundation, Athens, Greece). 29 November - 1 December 2013.

2012 **Second Workshop of the EU Regpot-NeuroSign Project**, "Functional analysis of CNS infiltrating cells during the development of CNS autoimmunity, injury and repair", Hellenic Pasteur Institute, Athens, Greece, 4-7 December 2012.

2009 **Fourth General Meeting of the EU NeuroproMiSe Consortium,** Athens Caravel, 8-10 November 2009.

2004 **Seventh International Congress of Neuroimmunology (ISNI),** Venice, Italy. Symposium organizer and chairperson, "Signaling Mechanisms in Brain Inflammation"

2002-present **European School of Neuroimmunology (ESNI).** Member of scientific & organizing committees.

Fifteenth ESNI Course, Prague, Czech Republic, June 2015. Programme committee, chair and lecturer

Ninth ESNI Course, Istanbul, Turkey, September 2009. Programme committee, one-day symposium organizer and chair, "Basic and clinical aspects of neuroinflammation" with talk "Neuronal control of brain inflammation".

Seventh ESNI Course, Oxford, UK, September 2007. Programme committee, one-day symposium organizer and chair, "Inflammation in neuroimmunology:basic mechanisms".

Sixth ESNI Course, Thessaloniki, Greece, September 2005. Talk "Immunoregulation of Th1 and Th2 responses in Neuroinflammation".

Fourth ESNI Course, Barcelona, Spain, September 2003. Programme committee, one-day symposium organizer and chair, "Neurodegeneration and Immunoregulation".

Third ESNI Course, Tampere, Finland, September 2002. Talk "Cytokine mediated brain damage".

1998 **Fifth International Congress of Neuroimmunology (ISNI)**, Montreal, Canada. Symposium organizer and chair, "TNF and Neuroimmune Responses".

1989 **International Meeting on Inflammatory Bowel Disease**, Athens Hilton, Greece.

ORGANIZATION OF SEMINARS AT HPI

2018 **David Baker,** Professor, Queen Mary University of London, UK. “Models for multiple sclerosis: EAE a model for the autoimmune components of MS”. September 2018.

2018 **David Baker**, Professor, Queen Mary University of London, UK. “MS models: translational approach”, September 2018.

2018 **Naoto Kawakami**, Professor, Institute of Clinical Neuroimmunology, LMU, Munich, Germany. “T cell interactions with the BBB”. September 2018.

2018 Trevor Owens, Professor, Univ. of Southern Denmark, Odense, Denmark. “Basic principles of BBB, cell migration into CNS”. September 2018.

2012 **Christopher Linington**, Professor and Chair in Neuroimmunology, Institute of Infection Immunity and Inflammation Medicine, University of Glasgow, UK. “Progressive multiple sclerosis - dysregulation of fibroblast growth factor 9 expression contributes to lesion development in the CNS”. July 2012.

Christopher Linington, Professor and Chair in Neuroimmunology, Institute of Infection Immunity and Inflammation Medicine, University of Glasgow, UK. “Experimental autoimmune encephalomyelitis: a valid model for multiple sclerosis?”. December 2012.

Hans Lassmann, Professor, Medical University of Vienna, Vienna, Austria. “How to translate mechanisms from basic experimental studies to human multiple sclerosis”. December 2012.

David Baker, Professor, Barts and The London School of Medicine and Dentistry. “Use and abuse of animal models of multiple sclerosis”. December 2012.

Roland Liblau, Centre de Physiopathologie de Toulouse-Purpan, Toulouse, France. “T cells and CNS autoimmunity”.

Edgar Meinl, Professor, Max-Planck-Institute of Neurobiology, Munich, Germany. “B cells and CNS autoimmunity”. December 2012.

George Kollias, Professor, Biomedical Sciences Research Centre Alexander Fleming, Vari, Greece. “Endothelial pathways in the regulation of CNS autoimmunity and repair”. December 2012.

Hartmut Wekerle, Professor, Max-Planck-Institute of Neurobiology, Munich, Germany. “In vivo imaging of immune-CNS cell interactions”.

Maria Evangelidou, Postdoctoral fellow, Hellenic Pasteur Institute, Athens, Greece. “T cell- neuron interactions in the CNS”. December 2012.

Roberto Furlan, Clinical Researcher, San Rafaele Scientific Institute, Milan, Italy. “Propagation of neuroinflammation by extracellular membrane vesicles”. December 2012.

Vivian Tseveleki, Postdoctoral fellow, Hellenic Pasteur Institute, Athens, Greece. “Re-establishing immune tolerance for multiple sclerosis therapy”. December 2012.

Antonio Uccelli, Professor, University of Genova, Genova, Italy. "Mesenchymal stem cells: Basics and therapeutic potential for multiple sclerosis". December 2012.

Nikolaos Grigoriadis, Professor, Aristotle University of Thessaloniki, Thessaloniki, Greece. “Stem cells as therapies for multiple sclerosis: Are we ready for clinical trials?” December 2012.

Krysztof Selmaj, Professor, Medical University of Lodz, Lodz, Poland. "Immune intervention leading to progress in multiple sclerosis therapy". December 2012.

2009 **David Attwell**, Jodrell Professor of Physiology, University College, UK. "Neurotransmitter signaling to oligodendrocytes in health & disease". May 2009.

2004 **John Quackenbush**, Professor of Computational Biology & Biostatistics, Dana Farber Cancer Institute & Harvard School of Public Health. Boston, USA. "Using Microarrays & Bioinformatics to Explore Biology". February 2004.

1997 **Yvonne de Kozak**, Head of Laboratory of Ophthalmic Immunopathology, INSERM, Paris. "Cytokines and nitric oxide in two ocular models of inflammation: LPS-induced uveitis and experimental autoimmune uveoretinitis". February 1997.

1996 **Jan Bauer**, Professor of Neuropathology, Div. of Neuroimmunology, Brain Research Institute, Vienna, Austria. "T-cell apoptosis in inflammatory brain lesions: destruction of T cells does not depend on antigen recognition". June 1996.

INVITED SEMINARS & TALKS

2018 **The role of TNF in the CNS- animal models**. The 5th Panhellenic Meeting of the Hellenic Academy of Neuroimmunology for Multiple Sclerosis, Thessaloniki, December 6-9, 2018.

2018 **TNF in demyelination and remyelination in the CNS**. Clinical Neuroimmunology Seminars, University of Athens Medical School, Athens, 4 May, 2018.

2017 **Towards humanized models for multiple sclerosis.** Transgenic technologies in modeling human diseases: principles, associated technologies, animal management and ethics. Hellenic Pasteur Institute, Athens, June 5-13, 2017.

2015 **Animal models for multiple sclerosis**. The 3rd Panhellenic Meeting of the Hellenic Academy of Neuroimmunology for Multiple Sclerosis, Athens, November 19-22, 2015.

Animal models of neuroinflammatory diseases: strengths and weaknesses. International Joint Israel-Greek-Italian Neuroimmunological Meeting, Elounda, Crete, 11-14 June 2015.

Animal models of neuroinflammatory diseases: strengths and weaknesses. The 15th ESNI Course, Prague, Czech Republic, June 1-4, 2015.

Animal models for multiple sclerosis. The 3rd Scientific Forum: From Washington to Porto Heli, Porto Heli, Greece, May 29- June 1, 2015.

2014 **Therapeutic approaches for the treatment of CNS auroimmunity and neuroinflammation.** University of Vigo, Vigo, Spain, October 24, 2014.

Animal models for multiple sclerosis. The 2nd Scientific Forum: From Philadelphia to Porto Heli, Porto Heli, Greece, June 13-15, 2014.

2012 **Neuronal control of CNS inflammation**. The Joint Israeli-Greek Neuroimmunological Meeting 2012, Porto Carras Hotel, Chalkidiki, Greece, June 29-July 2, 2012.

2011 **Re-establishing peripheral tolerance to CNS antigens for therapy in multiple sclerosis**. Hotel Cape Sounio, Attiki, Greece, September 30-October 2, 2011.

Tuning TNF as a target for therapy in CNS inflammation. Seventh Aegean Meeting on Neurological Therapeutics, Capsis Convention Centre, Heraklion, Crete, May 27-28, 2011.

De-sensitization of the immune system for therapy in multiple sclerosis. 62nd Meeting of the Hellenic Society for Biochemistry & Molecular Biology, Athens, Greece, December 2011.

2010 **The TNF-NFκB signaling axis in CNS neurons in health and disease**. COST Action B30, Nereplas, Final Meeting, Carmona, Spain, June 2010.

Fifth NeuroproMiSe Meeting, Rome, Italy, 21-22 October 2010.

2009 **Role of the neuronal TNFRI/ NF-κB signaling axis in the maintenance of CNS immune privilege and neuroprotection.** New developments in multiple sclerosis research, Groningen, The Netherlands, June 2009.

Neuronal Control of Inflammation. Ninth ESNI Course, Istanbul, Turkey, September 2009.

Fourth NeuroproMiSe Meeting, Athens, Greece, 9-10 November 2009.

2008 **Role of neuronal TNF ligand/receptor signalling axis in the maintenance of CNS immune privilege and neuroprotection**. Twenty-second Annual Meeting of the Hellenic Society for Neuroscience, Athens, Greece, October 2008.

Workshop on CNS Inflammation and Third NeuroproMiSe General Meeting, Toulouse, France, 3-5 November 2008.

Autoimmune neurodegenerative syndromes. Hellenic Research Foundation Workshop- Recent advances in the pathophysiology and treatment of neurodegenerative diseases, Athens Greece, June 2008.

Neuronal Control of Myelination. Gordon Research Conference Myelin, Il Ciocco, Italy, May 2008.

2007 Second NeuroproMiSe Meeting, Bonn, Germany, 12-13 November 2007.

2006 **Death receptor signaling pathways control neuron fate following ischemic injury**. COST Action B30, Nereplas, First Meeting, Carmona, Spain, November 2006.

First NeuroproMiSe Meeting, Rome, Italy, 6 November 2006.

2005 **Immunoregulation of Th1 and Th2 responses in neuroinflammation**. Sixth ESNI Course, Thessaloniki, Greece, September 2005.

2004 **Death receptor signaling pathways control neuron fate following ischemic injury**. Seventh International Congress of Neuroimmunology (ISNI), Venice, Italy, September 2004.

Immunoregulatory role of c-FLIP$_L$ in T lymphocytes. Keystone Symposium on Regulatory T cells, Banff, Canada, September 2004.

Visualisation of proliferative and cytotoxic mechanisms induced by TNF in transgenic mice as a means for understanding the development of inflammatory lesions. Educational Seminars in Science & Technology "Applications of Methodology in Light Microscopy in Biomedical Research and Diagnosis". Hellenic Pasteur Institute, May 2004.

2003 **Animal Models in Understanding Autoimmune Diseases**. Fourth Conference of Medical Chemistry: Drug Discovery and Design. University of Patras, Departments of Chemistry & Pharmacology, March 2003.

2002 **Neuroprotective effects of TNF/p55TNFR signaling in vivo following experimental ischemia are mediated by NF-κB.** Ninth TNF Superfamily Congress, San Diego, USA. September 2002.

Cytokine-mediated brain damage. Third ESNI Course Tampere, Finland, September 2002.

Animal Models in Understanding Autoimmune Diseases. Third Conference of Medical Chemistry: Drug Discovery and Design. University of Patras, Departments of Chemistry & Pharmacology, March 2002.
Functional genetics in mice. Harakopeio University, Athens. January 2002.
Towards understanding multiple sclerosis; modeling of disease mechanisms and therapeutic approaches in animals. Postgraduate Seminars in Immunology, Hellenic Pasteur Institute, January 2002.

2001 **Role of the TNF receptor family in cell death & survival in the CNS**. FEBS Advanced Course "From Differentiation to Death of Nerve Cells". Spetses, Greece, September 2001.
The role of TNF in EAE/MS: modeling of disease mechanisms and therapeutic approaches in animals. Fourteenth National Conference of Italian Immunology Society, Abano, Italy. June 6-9, 2001.
Transgenic Mice, Models for Human Disease, Educational Seminars "Modern Diagnostic Methodology in Infectious & Autoimmune Diseases", Hellenic Pasteur Institute, Athens, April 2001.
Use of Animal Models for Understanding Multiple Sclerosis. Second Conference of Medical Chemistry: Drug Discovery and Design. University of Patras, Departments of Chemistry & Pharmacology, March 2001.

2000 **Cross-talk between the immune and the nervous system: role of TNF in glial cell function and implications for pathology**. Fifteenth Annual Meeting of the Hellenic Society for Neuroscience, Patras, October 2000.

1999 **TNF-mediated protection of the eye during retina-targeted autoimmune disease studied in knockout mice**, Institute of Ophthalmic Research, INSERM, Paris, October 1999.
Transgenic and Knockout Models of TNF-induced Inflammation and Demyelination, Neurological Clinic, University Hospital of Szeged, Hungary, February 1999.
TNF and its receptors in CNS Function: Friend and Foe. Institute for Medical Research, Budapest, Hungary, February 1999.
The use of transgenic and knockout mice for the analysis of the immune and inflammatory activities of TNF in the CNS. Medical School, University of Athens, January 1999.

1998 **Transgenic and Knockout Models of TNF-induced Inflammation and Demyelination.** Ares-Serono, Geneva, Switzerland, November 1998.
The TNF/TNF receptor system in CNS Disease: studies in transgenic & mutant mice. Fifth ISNI Congress, Montreal, Canada, August 1998.
TNF ligand/receptor signalling induces MS-type plaques in the CNS of transgenic mice. Fifth International Congress of Neuroimmunology (ISNI), Montreal, Canada, August 23-27, 1998.
TNF and receptors in CNS function: Friend and Foe. Seventh TNF Congress, Hyannis, MA, USA, May 1998.
Transmembrane TNF signalling through p75TNFR induces inflammatory ischemia in the CNS of transgenic mice. Seventh TNF Congress, Hyannis, MA, USA, May 1998.
Transgenic models of TNF-alpha induced demyelination. Third European Meeting on Glial Function, Athens, Greece, May 1998.
Local TNF/p55TNF receptor signaling in the CNS of transgenic mice models multiple sclerosis. Eighteenth European Workshop for Rheumatology Research. Athens, March 1998.

1997 **TNF-mediated CNS inflammation and demyelination models chronic and acute multiple sclerosis**. International Symposium: Immunopathology of Multiple Sclerosis, University of Vienna, Austria, November 1997.

TNF-triggered CNS inflammation, demyelination and T cell autoreactivity in transgenic mice: A role for mature lymphocytes in disease modulation but not disease initiation. Thirteenth European Immunology Meeting, Amsterdam, The Netherlands, June 1997.

1996 **Autoimmune reactivity in a transgenic model of TNF alpha-triggered CNS inflammation and demyelination.** First Joint Meeting of the International Cytokine Society (ICS)/International Society for Cytokine Research (ISICR), Geneva, Switzerland, October 1996.

Transgenic animal models of TNF-mediated CNS pathology. Sixth International TNF Congress, Rhodes, May 1996.

1995 **Transgenic animal models of human neurodegenerative diseases: aiding drug design**. Biomed Workshop - Amino Acids, Peptides and Proteins/Drug Discovery and Design, University of Patras, Greece, November 1995.

1994 Text & Narrative for the Educational Video : "**Transgenic Mice**" showing transgenic technologies, Laboratory of Molecular Genetics, Hellenic Pasteur Institute, produced by the Agricultural Bank of Greece within the framework of the European programme COMMET/AGROBIOTECH. 1994.

1993 **Technologies for Analyzing Gene Expression & Function**. Seminars in Molecular Biology, Helleneic Pasteur Institute, November 1993.

1989 **Abnormalities of the enteric neuropeptide system in inflammatory bowel disease**. International Meeting on IBD, Athens, April 1989.

1983 **The ultrastructural localisation of neuropeptide Y (NPY)-immunoreactivity within the gut and its association with sympathetic nerves.** The 146th Meeting of the Pathological Society of Great Britain & Ireland, Edinburgh, Scotland. July 1983**.**

1983-1984 Teaching & Practical Demonstrations to undegraduate Biochemistry students in course "**Hormone Action**" and supervision of two undergraduate student research projects. Imperial College of Medicine, Science & Technology, University of London.

1981 **Substance P and VIP are present in distinct subpopulations of p-type enteric neurons.** The 143rd Meeting of the Pathological Society of Great Britain & Ireland, Dundee, Scotland, July 1981.

1980 **Ultrastructure of the gut innervation**. Postgraduate Histopathology Seminars; Mini-Symposium on Distribution and Tissue Localisation of Regulatory Peptides of the Gut, RPMS, Hammersmith Hospital, October 1980.

1980 **Immunoelectroncytochemistry of substance P.** Presented at the Meeting of Royal Society of Medicine, (Pathology Section), London, October 1980.

1979-1984 Teaching & Supervision during Postgraduate Course in **Histochemistry & Immunocytochemistry**. Royal Postgraduate Medical School, Hammersmith Hospital, University of London.

1979-1983 Teaching undergraduate students in **Anatomy, Physiology, Biology, Immunology, Electrophysiology and Electron Microscopy Courses**. University of London.

SUPERVISION OF DOCTORAL THESES

1. **Irini Papazian, MsC.,** Biologist
   "Different roles of soluble and transmembrane TNF during the development of inflammation of the CNS".
   Department of Medicine, School of Life Sciences, National & Kapodistrian University of Athens, Greece.
2. **Maria Karamita,** Molecular Biologist

"The role of cell-specific depletion of the transcription factor NF-κB in the development of inflammation and demyelination during neuroinflammatory disease of the CNS using conditionally gene-targeted mice".
Department of Medicine, School of Life Sciences, National & Kapodistrian University of Athens, Greece. March 2016. Currently Civil Servant, Greek National Health System (EOPYY), Kalymnos, Greece.

3. **Vassiliki Kyrargyri,** Biologist
"The role of the transcription factor NF-κB in neuron physiology and in diseases of the central nervous system" .
Department of Medicine, School of Life Sciences, National & Kapodistrian University of Athens, Greece. September 2014. Subsequently postdoctoral fellow, UCL Neuroscience, Physiology and Pharmacology, London, UK (2015-2018). Currently, postdoctoral fellow, Laboratory Molecular Genetics, Hellenic Pasteur Institute, Athens, Greece.
4. **Androniki Voulgari-Kokota,** Molecular Biologist
"Role of innate CNS inflammation in signaling neural and bone marrow-derived stem cells recruitment and tissue repair".
Department of Medicine, School of Life Sciences, National & Kapodistrian University of Athens, Greece. June 2012. Currently research assistant, Diagnostic Department, Hellenic Pasteur Institute, Athens, Greece.
5. **Maria Evangelidou**, Biologist
"Study of the role of caspase 8 in T lymphocyte differentiation and function using in vitro and transgenic mouse systems".
Department of Medicine, School of Life Sciences, National & Kapodistrian University of Athens, Greece. June 2010. Currently research assistant, Diagnostic Department, Hellenic Pasteur Institute, Athens, Greece.
6. **Mary Emmanouil**, Biologist
"Study of the cellular basis of TNF signaling during CNS inflammation, demyelination and repair in a mouse model of multiple sclerosis".
Department of Medicine, School of Life Sciences, National & Kapodistrian University of Athens, Greece. February 2010. Currently research assistant, Diagnostic Department, Hellenic Pasteur Institute, Athens, Greece.
7. **Giorgos Pissas,** Biologist
"Study of the role of the hepatitis C virus core/core+1 proteins in hepatic carcinoma using transgenic mice".
Department of Medicine, School of Life Sciences, National & Kapodistrian University of Athens, Greece.
8. **Erasmia Taoufik**, Biologist
"Study of the role of tumour necrosis factor (TNF) in cerebral ischaemia".
Department of Medicine, School of Life Sciences, National & Kapodistrian University of Athens, Greece. July 2007. Currently Researcher level C, Laboratory of Cellular & Molecular Neurobiology, Hellenic Pasteur Institute, Athens, Greece.
9. **Vivian Tseveleki**, Biochemist
"Study of the role of the apoptosis signaling pathway in T lymphocytes during immune responses. The contribution of death receptors of the TNF superfamily".
Department of Medicine, School of Life Sciences, National & Kapodistrian University of Athens, Greece. December 2006. Currently employed by Pharmaceutical Company, Athens, Greece.
10. **Ioanna Dagliani,** Chemist
"Study of the structure and biological activity of peptide mimetics of myelin basic protein (MBP)".
Department of Chemistry, School of Life Sciences, University of Patras, Greece. November 2002.

11. **Giorgos Kassiotis,** Biologist
    "Generation & characterization of transgenic mouse models for human neuroinflammatory diseases".
    Section of Genetics, Developmental and Molecular Biology, Department of Biology, School of Life Sciences, Aristotelion University of Thessaloniki, Greece. July 2000. Currently Researcher at MRC National Institute for Medical Research, Immunoregulation Group, London, UK.
12. **Katerina Akassoglou**, Biologist
    "Study of the role of tumour necrosis factor (TNF) in the nervous system by use of transgenic mice".
    Department of Biology, School of Life Sciences, National & Kapodistrian University of Athens, Greece. June 1998. Currently Professor of Neurology, UCSF, USA.

SUPERVISION OF MASTERS PROJECTS

1. **Athena Boutou, B.Sc. Biology**, M.Sc. student Athens International Masters Program in Neurosciences, National & Kapodistrian University of Athens, Greece. Research Project entitled "Study of the mechasnism by which TNF inhibits myelin phagocytosis by macrophages". September 2018-July 2019.
2. **Anastasia Dagonaki, B.Sc. Biology**, M.Sc. student Molecular & Applied Physiology course (supervised by Prof. M. Koutsilieris), School of Medicine, National & Kapodistrian University of Athens, Greece. Research Project entitled "Study of the role of T cell anergy in myelin-specific T cells upon their migration into the CNS". March 2016- July 2017.
3. **Pantelis Xenias, B.Sc. Biology,** M.Sc. student Molecular Medicine course (supervised by Prof. N. Anagnou), School of Medicine, National & Kapodistrian University of Athens, Greece. Rotation June 2014- September 2014. M.Sc. Research Project entitled "Study of the role of T cell proliferation in the development of experimental autoimmune encephalomyelitis". October 2014- August 2015.
4. **Fotios Lampros**, **B.Sc. Biology**, M.Sc. student Southern Denmark University, Denmark. M.Sc. Research Project entitled "Evaluation of mannan-conjugated myelin antigens as an immunotherapy strategy for inducing T cell tolerance and protection against experimental autoimmune encephalomyelitis in an HLA-DR2 humanized mouse model for multiple sclerosis". September 2014- August 2015.
5. **Eirini Sfyroera, B.Sc. Biology**, MSc student Molecular Medicine course (supervised by Prof. N. Anagnou), School of Medicine, National & Kapodistrian University of Athens, Greece. Rotation February 2014-June 2014.
6. **Eirini Papazian, B.Sc. Biology**, M.Sc. student, Molecular and Applied Physiology course (supervised by Prof. M Koutsilieris), School of Medicine, National & Kapodistrian University of Athens, Greece., project entitled "Study of the changes in phenotype induced in cortical neuron cultures by mesenchymal stem cells during neuroprotection against glutamate-induced cell death", February 2012-December 2012.
7. **Nikos Simos, B.Sc. Mathematics,** M.Sc. student Bioinformatics course, Wageningen University, Netherlands. MSc Research Project entitled "Approaches to analyze and integrate data from microarray gene expression analyses of brain in three mouse models of human CNS neurodegenerative disease". March-May 2006.

SUPERVISION OF UNDERGRADUATE PROJECTS ("DIPLOMATIKI")

1. **Eleni Tsoukala**, Biology student, National & Kapodistrian University of Athens, Greece. 4th year B.Sc. project, title "Study of the role of neuronal TNFR1 in vitro and in vivo in

models of neuroprotection and neurotoxicity using conditional gene-targeting in mice" September 2017-July 2018.

2. **Athena Boutou**, Biology student, National & Kapodistrian University of Athens, Greece. 4th year B.Sc. project, title "Study of the mechanisms of neuroprotection mediated by TNF receptors 1 and 2 *in vivo* using conditionally gene-targeted mice" September 2016-July 2017.
3. **Lida Iliopoulou**, Biology student, National & Kapodistrian University of Athens, Greece. 4th year B.Sc. project, title "Study of the mechanisms of neuroprotection mediated by TNF receptors 1 and 2 *in vitro* and *in vivo* using conditionally gene-targeted mice" October 2015-June 2016.
4. **Maria Avloniti**, Biology student, National & Kapodistrian University of Athens, Greece. 4th year B.Sc. project, title "Analysis of the interactions between dendritic cells and T lymphocytes in the induction of immune tolerance for the therapy of autoimmune diseases of the central nervous system", October 2014-July 2015.
5. **Marina Papoulia**, Department of Biological Applications and Technologies, University of Ioannina, Greece. 4th year B.Sc. Project entitled "Study of the role of NF-κB in brain microglial cells during neurodegenerative disease using transgenic mouse models". July 2012, September 2012-December 2013.
6. **Michael Makryllos**, Molecular Biology & Genetics student, University of Thrace, Greece. 4th year Undergraduate Project entitled "Design and construction of a conditional BACs transgene for expression of the human TNFR1 in mice". February 2009- June 2011.
7. **Areti Manta**, Biology student, National & Kapodistrian University of Athens, Greece. 4th year Undergraduate Project entitled "Study of the role of caspase 8 in T cell activation through the T cell receptor using caspase 8 mutants in human T lymphocytes (Jurkat cells)". December 2007- June 2008.
8. **Sophia Beina**, Biology student, National & Kapodistrian University of Athens, Greece. 4th year Undergraduate Project entitled "Study of the cell-specific roles of NF-κB in the development of CNS inflammation in a multiple sclerosis model". October 2007- May 2008.
9. **Michael Koutrollos,** Biology student, National & Kapodistrian University of Athens, Greece. 4th year Undergraduate Project entitled "Study of the role of the neuronal NF-κB/FLIP axis in neuroprotection during experimental autoimmune encephalomyelitis". October 2006- May 2007.
10. **Maria Karamita,** Molecular Biology & Genetics student, University of Thrace, Greece. 4th year Undergraduate Project entitled "Characterization of a conditional gene targeting system in endothelial cells with the aim of investigating the role of inflammation in the brain". March-September 2006.
11. **Athanassia Stathopoulou**, Molecular Biology & Genetics student, University of Thrace, Greece. 4th year Undergraduate Project entitled "Study of the role of caspase 8 in T cell function through the use of siRNA" March 2005- August 2005.
12. **Thomas Alexandris**, Biotechnology student, University of Aberdeen, Scotland. 4th year Undergraduate Project entitled "Study of the role of the long isoform of c-FLIP (c-FLIPL) in TNF/TNFR1 induced NF-kB activation and cytoprotection". October 2004-August 2005.
13. **Orestis Argyros**, Molecular & Cellular Biology student, University of Aberdeen, Scotland. 4th year Undergraduate Project entitled "Role of TNF in the cells of the oligodendrocyte lineage". October 2002-August 2003.
14. **Elena Odiatou**, Biology student, National & Kapodistrian University of Athens, Greece. 4th year Undergraduate Project entitled "Study of the role of TNF in experimental autoimmune uveitis using transgenic mice". October 2001-August 2002.

SUPERVISION OF PRACTICAL LABORATORY EXPERIENCE

1. **Konstantinos Kontodimas**, Biology student, Boston University, Boston, USA. Practical laboratory experience for 2 weeks during 2nd year of BSc degree, July 2018.
2. **Orestis Katsoulis**, Biology student, University of Newcastle, England, UK. Practical laboratory experience for 1.5 months during 2nd year of BSc degree, June-July 2018.
3. **Ioanna Pyromali**, Biology student, University of Newcastle, England, UK. Practical laboratory experience for 1.5 months during 2nd year of BSc degree, June-July 2018.
4. **Katerina Panagiotidi**, Biology student, University of Edinburgh, Scotland, UK. Practical laboratory experience for 2 weeks during 2nd year of BSc degree, July 2018.
5. **Katerina Loupasaki,** IB High School student, Athens College, Athens. Practical laboratory experience for 2 week at end of 1st year IB course, July 2018.
6. **Alexander Patellis**, Biology student, University of Crete, Greece. Practical laboratory experience for 1 month during 2nd year of BSc degree, July 2017.
7. **Magda Kreouzi**, Medical student, Medical School of National & Kapodistrian University of Athens, Greece. Practical laboratory experience for 1 month during 1st year of Medical degree, June 2017.
8. **Afroditi Pinialidi**, Forensic Biology student, Manchester Metropolitan University, Manchester, UK. Practical laboratory experience for 1.5 months during 2nd year of BSc degree June-July 2017.
9. **Lily Kokoti**, Medical student, Medical School of National & Kapodistrian University of Athens, Greece. Practical laboratory experience (histopathology) during 5th year of Medical degree, May-July 2017.
10. **Anna Maria Mavriyiannaki**, IB High School student, Moraitis School, Athens. Practical laboratory experience for 1 week at end of 2nd year IB course, July 2016.
11. **Elena Markoulaki**, Biology student, National & Kapodistrian University of Athens, Greece. Practical laboratory experience for 1 month during 2nd year of BSc degree, August 2016.
12. **Evi Vlachou**, Biology student, National & Kapodistrian University of Athens, Greece. Practical laboratory experience for 2.5 months during 2nd year of BSc degree, June-August 2016.
13. **Lida Iliopoulou**, Biology student, National & Kapodistrian University of Athens, Greece. Practical laboratory experience for 4 months during 2nd year of BSc degree, July 2015-October 2015.
14. **Chris Vrettos**, IB High School student, Moraitis School, Athens. Practical laboratory experience for 1 week at end of 2nd year IB course, July 2014. Now undergraduate student in Biology at UCL, London, UK.
15. **Dafni Tzini**, IB High School student, Moraitis School, Athens. Practical laboratory experience for 1 week at end of 2nd year IB course, July 2014.
16. **Maria Avloniti**, Biology student, National & Kapodistrian University of Athens, Greece. Practical laboratory experience for 4 months during 2nd year of BSc degree with project title “Analyzing dendritic cell-T cell interactions in autoimmune disease of the central nervous system”, February 2014-June 2014.
17. **Eleni Hatzivagia**, Biochemistry & Biotechnology student, University of Thessalia, Greece. Practical laboratory experience for 2 months during 2nd year of BSc degree, July 2013-August 2013.
18. **Panayiotis-Orpheas Protopsaltis**, Biology student, National & Kapodistrian University of Athens, Greece. Practical laboratory experience for 3 months during 2nd year of BSc degree, February-May 2008.
19. **Konstantina Ioannidou**, Biology student, University of Patras. Practical laboratory experience in 4th year of BSc degree, January-July 2011.
20. **Amalia Stantzou,** Biology student, Universite Pierre et Marie Curie, Paris, France. Practical laboratory experience in 2nd year of BSc degree, June-July 2008.

21. **Christos Georgiadis**, Biochemistry student, College of Life Sciences, University of Dundee, UK. Practical laboratory experience in 2nd year of BSc degree "Gene expression profiling of CNS diseases in mouse models for the discovery of specific pathogenic pathways and innate tissue defense responses". June-July 2007.
22. **Eirini Papadaki**, Biochemistry & Biotechnology student, University of Thessalia, Greece. July-August 2004.
23. **Marianna Georgakopoulou**, Psychology student, Panteon University, Athens, Greece. October 2002-August 2003.
24. **Sandrine Billet**, Biochemistry student, University Pierre et Marie Curie (Paris VI). "Study of the role of FLIP as a regulator of T cell function during experimental autoimmune encephalomyelitis". July- August 2000.

SPECIALIZED TRAINING &TRANSFER OF KNOWLEDGE

Members of my research team are encouraged to attend specialized courses and to visit other Institutes in the context of ongoing research collaborations so that they can further their knowledge and technical expertise, and also transfer this knowledge to HPI. Following are main examples:

Flow cytometry (FACS)

- PhD student participation in International School of Flow Cytometry **(**IFCS) "Antigen Specific T Cell Flow Cytometry", Munich, Germany, September 2003 (Vivian Tseveleki, supported by IFCS stipend).
- PhD student hosted for four months in the Laboratories of Professor Andreas Radbruch and Dr. Alexander Sheffold, DRFZ German Rheumatology Research Centre, Berlin, Germany (Vivian Tseveleki, supported by studentship from DAAD- German Academic Exchange Service, Bonn, Germany).

cDNA microarrays and bioinformatics

- PhD student participation in EMBO practical course "DNA Microarrays: Applications and Data Analysis", September 2001, EMBL Heidelberg, Germany (Vivian Tseveleki, supported by EMBO stipend)
- PhD student hosted for two one-month periods in the Laboratory of Dr. John Quackenbush, The Institute for Genomic Research, Washington, USA. March 2004, July 2004 (Vivian Tseveleki, supported by research grant from Greek Secretariat of Science & Technology, Bilateral R&T Collaboration Greece-USA).

Conditional gene targeting in mice

- PhD student participation in EMBO practical course "Mouse Genome Engineering by Site-Specific recombinases", September 2001, Brunsweig, Germany (Era Taoufik, supported by EMBO stipend).

Modern methods in neuropathology

- PhD student hosted for two months by Professor Hans Lassmann, Laboratory of Experimental Neuropathology, Brain Research Institute, Medical University of Vienna, Austria. September 1996 (Katerina Akassoglou, supported by EMBO fellowship).
- PhD student participation in the one-week COST Action Neurinfnet Training School, Neuroimmune Interactions held in Braga, Portugal, June 2009 (Maria Karamita, supported by ESF COST Action Neurinfnet BM0603).
- PhD student hosted for one month by Professor Hans Lassmann, Laboratory of Experimental Neuropathology, Brain Research Institute, Medical University of Vienna, Austria. May 2011 (Maria Karamita, supported by ESF COST Action Neurinfnet BM0603 STSM).

Isolation and manipulation of T lymphocytes for study in vitro and in vivo

- PhD student hosted for two months by Professor Hartmut Wekerle, Max-Planck-Institute of Neurobiology, Martinsried, Germany, July 1996 (Giorgos Kassiotis, supported by an EMBO fellowship).
- Postdoctoral researcher hosted for two weeks by Professor Hartmut Wekerle and Dr Guru Krishnamoorthy, Max-Planck-Institute of Neurobiology, Martinsried, Germany, November 2009 to learn to isolate CNS-infiltrating monocytes from mice with EAE and to induce adoptive T cell transfer EAE (Dr Vivian Tseveleki, supported by COST Action Neurinfnet BM0603 STSM).

Electrophysiology-induction of LTP and LTD in acute murine hippocampal slices

- PhD student hosted for three months by Dr Ana Sebastiao, University of Lisbon, Portugal, February-April 2009 (Vassiliki Kyrargiri, supported by ESF COST Action Nereplas B30 STSM).
- PhD student hosted for two weeks by Professor David Attwell, Department of Neuroscience, Physiology and Pharmacology, University College London, September 2010 (Vassiliki Kyrargyri, supported by ESF COST Action Neurinfnet BM0603 STSM).

Experimental cerebral ischemia and spinal cord injury

- Researcher hosted for five days by Professor Nikolaus Plesnila, Laboratory of Experimental Stroke Research, Institute for Stroke and Dementia Research (ISD), LMU Munich Medical School, December 2012, to acquire expertise in modeling and analyzing cerebral stroke and spinal cord injury in mice (Dr Era Taoufik, supported by FP6 REGPOT program).

Multiphoton microscopy for live imaging in spinal cord and brain

- Postdoctoral researcher hosted for two weeks in the laboratory of Dr Naoto Kawakami, Max-Planck-Institute of Neurobiology, Martinsried, Germany, March 2011 to acquire expertise in the use of multiphoton microscopy, which allows deep tissue penetration in tissue slices and live anaesthetized mice, and, without thermal damage. Using T cell transfer techniques important features of inflammatory neurodegeneration such as neuro - immune interactions were visualized during the development of CNS pathology (Dr Maria Evangelidou, supported by FP6 REGPOT program).

PUBLICATIONS IN INTERNATIONAL JOURNALS

h-index 40

1. **Probert L**, Avloniti M, Evangelidou M, Kanistras I, Anagnostouli M, Tseveleki V, Lampros F, Tselios T, Torp Jensen L, Kilindireas K, Matsoukas J, Lassmann H. Mannan-conjugated myelin peptides induce T cell anergy in humanized DR2 mice and reduce T cell responses in multiple sclerosis. Submitted for publication, January 2018.
2. Papazian I, Voulgari-Kokota A, Kyrargyri V, Evangelidou M, **Probert L**. (2018). Mesenchymal stem cell protection of neurons against glutamate excitotoxicity involves reduction of NMDA-triggered calcium responses and surface GluR1, and is partly mediated by TNF. Int. J. Mol. Sci. 2018, 19, 651; doi:10.3390/ijms19020651.
3. Emmanouil M, Tseveleki V, Friligou I, Deli A, Tselios T, **Probert L**. A cyclized altered peptide analogue based on myelin basic protein 87-99 provides lasting prophylactic and therapeutic protection against acute experimental autoimmune encephalomyelitis. Molecules. 2018 Jan 31;23(2). pii: E304. doi: 10.3390/molecules23020304.
4. Karamita M, Barnum C, Mobius W, Tansey MG, Szymkowski DE, Lassmann H, **Probert L**. (2017). Brain inhibition of soluble TNF permits remyelination during active demyelination. *J. Clin. Invest. Insight*, Apr 20;2(8). pii: 87455. doi: 10.1172/jci.insight.87455. Epub ahead of print.

5. Alé A, Bruna J, Calls A, Karamita M, Haralambous S, **Probert L,** Navarro X, Udina E. (2016). Inhibition of the neuronal NFκB pathway attenuates bortezomib-induced neuropathy in a mouse model. *Neurotoxicology.* July 2016;55:58-64. doi: 10.1016/j.neuro.2016.05.004. Epub 2016 May 19.
6. **Probert L** (2015). TNF and its receptors in the CNS: the essential, the desirable and the deleterious effects. *Neuroscience* Aug 27;302:2-22. doi: 10.1016/ j.neuroscience. 2015.06.038. Epub 2015 Jun 24. Review.
7. Tseveleki V, Tselios T, Kanistras I, Koutsoni O, Karamita M, Vamvakas SS, Apostolopoulos V, Dotsika E, Matsoukas J, Lassmann H, **Probert L** (2015). Mannan-conjugated myelin peptides prime non-pathogenic Th1 and Th17 cells and ameliorate experimental autoimmune encephalomyelitis. *Exp. Neurol*. 267:254-67; doi: 10.1016/j.expneurol.2014.10.019. Epub 2014 Oct 30.
8. Kyrargyri V, Vega-Flores G, Gruart A, Delgado-Garcia JM, **Probert L** (2015). Differential contributions of microglia and neuronal IKKβ to synaptic plasticity and associative learning in alert behaving mice. *Glia* Apr; 63 (4): 549-566; doi: 10.1002/glia.22756. Epub 2014 Oct 9.
9. Evangelidou M, Karamita M, Vamvakas SS, Szymkowski DE, **Probert L** (2015). Altered expression of oligodendrocyte and neuronal marker genes predicts the clinical onset of autoimmune encephalomyelitis and indicates the effectiveness of multiple sclerosis-directed therapeutics. *J Immunol.* May ;192(9):4122-33. doi: 10.4049/jimmunol.1300633. Epub 2014 Mar 28.
10. Schuh C, Wimmer I, Hametner S, Haider L, Van Dam A-M, Liblau RS, Smith KJ, **Probert L**, Binder CJ, Bauer J, Bradl M, Mahad D, Lassmann H (2014). Oxidative tissue injury in multiple sclerosis is only partly reflected in experimental disease models. *Acta Neuropathol.* Aug;128(2):247-66. doi: 10.1007/s00401-014-1263-5. Epub 2014 Mar 13.
11. Voulgari-Kokota A, Fairless R, Karamita M, Kyrargyri V, Tseveleki V, Evangelidou M, Delorme B, Charbord P, Diem R, **Probert L** (2012). Mesenchymal stem cells protect CNS neurons against glutamate excitotoxicity by inhibiting glutamate receptor expression and function. *Exp. Neurol*. Jul;236(1):161-70. doi: 10.1016/j.expneurol.2012.04.011. Epub 2012 Apr 25.
12. Taoufik E, Tseveleki V, Chu SY, Tselios T, Karin M, Szymkowski DE, Lassmann H, **Probert L** (2011) Transmembrane TNF is neuroprotective and regulates experimental autoimmune encephalomyelitis via neuronal NF-κB. *Brain* Sep;134(Pt 9):2722-35. doi: 10.1093/brain/awr203.
13. Emmanouil M, Taoufik E, Tseveleki V, Vamvakas S-S, **Probert L** (2011). A Role for Neuronal NF-κB in Suppressing Neuroinflammation and Promoting Neuroprotection in the CNS. *Adv Exp Med Biol.*691:575-81; doi: 10.1007/978-1-4419-6612-4_60.
14. Ghezzi P, Bernaudin M, Bianchi R, Blomgren K, Brines M, Campana W, Cavaletti G, Cerami A, Chopp M, Coleman T, Digicaylioglu M, Ehrenreich H, Erbayraktar S, Erbayraktar Z, Gassmann M, Genc S, Gokmen N, Grasso G, Juul S, Lipton SA, Hand CC, Latini R, Lauria G, Leist M, Newton SS, Petit E, **Probert L**, Sfacteria A, Siren AL, Talan M, Thiemermann C, Westenbrink D, Yaqoob M, Zhu C (2011). Erythropoietin: not just about erythropoiesis. *Lancet*. Jun 19;375(9732):2142.
15. Tseveleki V, Rubio R, Vamvakas S-S, White J, Taoufik E, Petit E, Quackenbush J, **Probert L** (2010). Comparative gene expression analysis in mouse models for multiple sclerosis, Alzheimer's disease and stroke for identifying commonly regulated and disease-specific changes. *Genomics* Aug;96(2):82-91. Epub 2010 May 7.
16. Evangelidou M, Tseveleki V, Vamvakas S-S, **Probert L** (2010). TNFRI is a positive T-cell costimulatory molecule important for the timing of cytokine responses. *Immunol. Cell Biol*. Jul; 88(5):586-95. Epub 2010 Mar 9.

17. Emmanouil M, Taoufik E, Tseveleki V, Vamvakas S-S, Tselios T, Karin M, Lassmann H, **Probert L** (2009). Neuronal IkappaB kinase beta protects mice from autoimmune encephalomyelitis by mediating neuroprotective and immunosuppressive effects in the central nervous system. *J Immunol*. 183(12):7877-89.
18. Moumtzi SS, Roberts ML, Joyce T, Evangelidou M, **Probert L**, Frillingos S, Fotsis T, Pintzas A (2009). Gene Expression Profile Associated with Oncogenic Ras-induced Senescence, Cell Death, and Transforming Properties in Human Cells. *Cancer Invest.* 28(6):563-87.
19. Oikonomou E, Makrodouli E, Evagelidou M, Joyce T, **Probert L**, Pintzas A (2009). BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells. *Neoplasia* 11(11):1116-31.
20. Taoufik E & **Probert L** (2008). Ischemic neuronal damage. *Curr.Pharm.Des*. 14: 3565-3573.
21. Taoufik E, Petit E, Divoux D, Tseveleki V, Mengozzi M, Roberts ML, Valable S, Ghezzi P, Quackenbush J, Brines M, Cerami A & **Probert L** (2008). TNF receptor I sensitizes neurons to erythropoietin- and VEGF-mediated neuroprotection after ischemic and excitotoxic injury. *PNAS USA* 105: 6185-6190.
22. Quinones MP, Kalkonde Y, Estrada CA, Jimenez F, Ramirez R, Mahimainathan L, Mummidi S, Choudhury GG, Martinez H, Adams L, Mack M, Reddick RL, Maffi S, Haralambous S, **Probert L**, Ahuja SK, Ahuja SS (2008).Role of astrocytes and chemokine systems in acute TNFalpha induced demyelinating syndrome: CCR2-dependent signals promote astrocyte activation and survival via NF-kappaB and Akt. *Mol.Cell.Neurosci.* 37(1):96-109.
23. Taoufik E, Tseveleki V, Euagelidou M, Emmanouil M, Voulgari-Kokota A, Haralambous S, **Probert L** (2008). Positive and negative implications of tumor necrosis factor neutralization for the pathogenesis of multiple sclerosis. *Neurodegener.Dis.* 5(1):32-7.
24. Tseveleki V, Tsagosis P, Koutsoni O, Dotsika E & **Probert L** (2007). Cellular FLIP long isoform transgenic mice overcome inherent T_h2-biased immune responses to efficiently resolve *Leishmania major* infection. *Int.Immunol.* 19: 1183-1189.
25. Oikonomou E, Kothonidis K, Taoufik E, **Probert E**, Zografos G, Nasioulas G, Andera L, Pintzas A (2007). Newly established tumourigenic primary human colon cancer cell lines are sensitive to TRAIL-induced apoptosis in vitro and in vivo. *Br.J.Cancer* 97(1): 73-84.
26. Taoufik E, Valable S, Muller G, Roberts ML, Divoux D, Tinel A, Voulgari-Kokota A, Tseveleki V, Altruda F, Lassmann H, Petit E & **Probert L** (2007). $FLIP_L$ protects neurons against in vivo ischemia and in vitro glucose-deprivation-induced cell death. *J.Neurosci.* 27 (25): 6633-6646.
27. Mastronardi FG, Wood DD, Mei J, Raijmakers R, Tseveleki V, Dosch H-M, **Probert L**, Casaccia-Bonnefil P & Moscarello MA (2006). Increased citrullination of histone H3 in multiple sclerosis brain and animal models of demyelination: a role for tumor necrosis factor-induced peptidylarginine deiminase 4 translocation. *J.Neurosci.* 26: 11387-11396.
28. Tseveleki V, Bauer J, Taoufik E, Ruan C, Leondiadis L, Haralambous S, Lassmann H & **Probert L** (2004). c-FLIPL overexpression in T cells is sufficient to drive Th2 effector responses and immunoregulation of experimental autoimmune encephalomyelitis. *J.Immunol.* 173: 6619-6626.
29. Tsagozis P, Tseveleki V, **Probert L**, Dotsika E, Karagouni E (2004). Vccination with plasmids encoding the Leishmania major gp63 glycoprotein and CD40L results in a partial suppression of the inflammatory reaction after experimental infection. *Eur.J.Inflamm.* 2 (2): 1-6.
30. Akassoglou K, Adams R, Bauer J, Mercado P, Tseveleki V, **Probert L**, Lassmann H & Strickland S (2004). Fibrin depletion decreases inflammation and delays the onset of demyelination in a tumor factor transgenic mouse model for multiple sclerosis. *PNAS USA,* 101: 6698-6703.

31. Akassoglou K, Douni E, Bauer J, Lassmann H, Kollias G & **Probert L** (2003). Exclusive tumor necrosis factor (TNF) signaling by the p75TNF receptor triggers inflammatory ischaemia in the CNS of transgenic mice. *PNAS USA*, 100(2): 709-714.
32. Tselios T, Apostolopoulou V, Daliani I, Deraos S, Grdadolnik S, Mavromoustakos T, Melachrinou M, Thymianou S, **Probert L**, Mouzaki A, Matsoukas J (2002). Antagonistic effectes of human cyclic MBP (87-99) altered peptide ligands in experimental allergic encephalomyelitis and human T-cell proliferation. *J.Med.Chem.* 45(2): 275-283.
33. **Probert L**, Akassoglou K (2001). Glial expression of cytokines in transgenic animals- how do these models reflect the "normal situation". Invited Review. *Glia* , 36, 212-219.
34. Tselios T, Daliani I, **Probert L**, Deraos S, Matsoukas E, Roy S, Pires J, Moore G & Matsoukas J (2000). Treatment of experimental allergic encephalomyelitis (EAE) induced by guinea pig myelin basic protein epitope 72-85 with a human MBP 87-99 analogue and effects of cyclic peptides. *Bioorgan.Med.Chem.* 8: 1903-1909.
35. Tselios T, Daliani I, Deraos S, Thymianou S, Matsoukas E, Troganis A, Gerothanassis I, Mouzaki A, Mavromoustakos T, **Probert L**, & Matsoukas J (2000). Treatment of experimental allergic encephalomyelitis (EAE) by a rationally designed cyclic analogue of myelin basic protein (MBP) epitope 72-85. *Bioorgan.Med.Chem.Lett.* 10: 2713-2717.
36. **Probert L**, Eugster H-P, Akassoglou K, Bauer J, Frei K, Lassmann H & Fontana A (2000). TNFR1signalling is critical for demyelination and the limitation of T-cell responses during immune-mediated CNS disease. Review, *Brain* 123, 2005-2019.
37. Fiore M, Angelucci F, Alleva E, Branchi I, **Probert L**, Aloe L (2000). Learning performances, brain NGF distribution and NPY levels in transgenic mice expressing TNF-alpha. *Beh.Brain Res*. 112: 165-175.
38. Tselios T, **Probert L**, Kollias G, Daliani I, Matsoukas E, Troganis A, Gerothanassis IP, Mavromoustakos T, Moore GJ & Matsoukas JM (1999). Design and synthesis of a potent cyclic analogue of the myelin basic protein epitope MBP72-85: Importance of the Ala81 carboxyl group and of a cyclic conformation for induction of experimental allergic encephalomyelitis. *J.Med.Chem.* 42: 1170-1177.
39. Kassiotis G, Bauer J, Akassoglou K, Lassmann H, Kollias G & **Probert L** (1999). A tumor necrosis factor-induced model of human primary demyelinating diseases develops in immunodeficient mice. *Eur.J.Immunol.* 29: 912-917.
40. Kassiotis G, Pasparakis M, Kollias G & **Probert L (**1999).TNF accelerates the onset but does not alter the incidence and severity of myelin basic protein-induced experimental autoimmune encephalomyelitis. *Eur.J.Immunol.* 29: 774-780.
41. Glosli H, Veiby OP, Fjerdingstad H, Mehlum A, **Probert L**, Kollias G, Gjernes E, Prydz H. (1999). Effects of hTNF alpha expression in T cells on haematopoiesis in transgenic mice. *Eur. J. Haematol.* 63: 50-60.
42. Aloe L, Fiore M, **Probert L**, Turrini P & Tirassa P (1999). Overexpression of tumour necrosis factor alpha in the brain of transgenic mice differentially alters nerve growth factor levels and choline acetyltransferase activity. *Cytokine* 11: 45-54.
43. Aloe L, Properzi F, **Probert L**, Akassoglou K, Kassiotis G, Micera A & Fiore M (1999). Learning abilities, NGF and BDNF brain levels in two lines of TNF-α transgenic mice, one characterized by neurological disorders, the other phenotypically normal. *Brain Res.* 840: 125-137.
44. Akassoglou K, Bauer J, Kassiotis G, Lassmann H, Kollias G & **Probert L** (1999). Transgenic models of TNF induced demyelination. *Adv.Exp.Med.Biol.* 468: 245-259.
45. Tselios T, **Probert L**, Kollias G, Matsoukas E, Roumelioti P, Alexopoulos K, Moore GJ & Matsoukas J (1998). Design and synthesis of small semi-mimetic peptides with immunomodulatory activity based on myelin basic protein (MBP). *Amino Acids* 14: 333-341.
46. Fiore M, Alleva E, **Probert L**, Kollias G, Angelucci F & Aloe L (1998) Exploratory and displacement behaviour in transgenic mice expressing high levels of brain TNF alpha. *Physiol.Behav.* 63: 571-576.

47. Alonzi T, Fattori E, Lazzaro D, Costa P, **Probert L**, Kollias G, De Benedetti F, Poli V & Ciliberto G (1998) Interleukin 6 is required for the development of collagen-induced arthritis. *J.Exp.Med.* 187: 461-468.
48. Akassoglou K, Bauer J, Kassiotis G, Pasparakis M, Lassmann H, Kollias G & **Probert L** (1998). Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the CNS of transgenic mice: Models for Multiple Sclerosis with primary oligodendropathy. *Am.J.Pathol*. 153: 801-813.
49. Tselios T, Deraos S, Matsoukas E, Panagiotopoulos D, Matsoukas J, Moore G J, **Probert L**, Kollias G, Hilliard B, Rostami A & Monos D (1997) Myelin basic protein peptides: induction and inhibition of experimental allergic encephalomyelitis. *Rev.Clin.Pharmacol.Pharmokin.* 11: (2&3) 60-64.
50. **Probert L** & Selmaj K (1997) TNF and related molecules: Trends in neuroscience and clinical applications. *J.Neuroimmunol.* 72: 113-117. Review.
51. **Probert L**, Akassoglou K, Kassiotis G, Pasparakis M, Alexopoulou L & Kollias G (1997) TNF alpha transgenic and knockout models of CNS inflammation and degeneration. *J.Neuroimmunol.* 72 137-141. Review.
52. Cope AP, Liblau RS, Yang X-D, Congia M, Laudanna C, Schreiber RD, **Probert L**, Kollias G & McDevitt HO (1997) Chronic tumor necrosis factor (TNF) alters T cell responses by attenuating T cell receptor signalling. *J.Exp.Med.* 185: 1573-1584.
53. Akassoglou K, **Probert L**, Kontogeorgos G & Kollias G (1997) Astrocyte- but not Neuron-Specific Transmembrane TNF Triggers Inflammation, Demyelination and Neuronal Degeneration in the CNS of Transgenic Mice. *J.Immunol.* 158: 438-445.
54. **Probert L**, Akassoglou K, Alexopoulou L, Douni E, Haralambous S, Hill S, Kassiotis G, Kontoyiannis D, Pasparakis M, Plows D & Kollias G (1996) Dissection of the pathologies induced by transmembrane and wild-type tumor necrosis factor in transgenic mice. *J.Leuk.Biol*. 59: 518-525. Review.
55. Fiore M, **Probert L**, Kollias G, Akassoglou K, Alleva E & Aloe L (1996) Neuro-behavioural alterations in developing transgenic mice expressing human TNF alpha in the brain. *Brain Behav.Immun.* 10: 126-138.
56. Douni E, Akassoglou K, Alexopoulou L, Georgopoulos S, Haralambous S, Hill S, Kassiotis G, Kontoyiannis D, Pasparakis M, Plows D, **Probert L** & Kollias G (1996) Transgenic and knockout analyses of the role of TNF in immune regulation and disease pathogenesis. *J.Inflamm.* 47: 27-38. Review.
57. Siegel SA, Shealy DJ, Nakada MT, Le J, Wolfe DS, **Probert L**, Kollias G, Ghrayeb J, Vilcek J & Daddona PE (1995) The mouse/human chimeric monoclonal antibody Ca2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. *Cytokine* 7: 15-25. ***Pre-clinical trial of Ca2 anti-TNF antibody now used in RA patients.**
58. **Probert L**, Plows D, Kontogeorgos G & Kollias G. (1995) The type I IL-1 receptor acts in series with TNF to induce arthritis in TNF transgenic mice. *Eur.J.Immunol*. 25: 1794-1797.
59. **Probert L**, Akassoglou K, Pasparakis M, Kontogiorgos G & Kollias G (1995) Spontaneous inflammatory demyelinating disease in transgenic mice showing CNS-specific expression of tumor necrosis factor. *PNAS USA* 92: 11294-11298.
60. Plows D, **Probert L**, Georgopoulos S, Alexopoulou L & Kollias G. The role of tumour necrosis factor (TNF) in arthritis: studies in transgenic mice. Proceedings of the XIIIth *Eur.Congr.Rheumatol.* (ERASS) 20-23rd June 1995. Vol 24 suppl. 2: 51-54.
61. Aloe L, **Probert L**, Kollias L, Micera A & Tirassa P (1995). Effect of NGF antibodies on mast cell distribution, histamine and substance P levels in the knee joint of TNF-arthritic transgenic mice. *Rheumat.Int.* 14: 249-252.
62. Taverne J, Sheikh N, de Souza JB, Playfair JHL, **Probert L** & Kollias G (1994) Anaemia and resistance to malaria in transgenic mice expressing human TNF. *Immunol.* 82: 397-403.

63. **Probert L**, Keffer J, Corbella P, Cazlaris H, Patsavoudi E, Stephens S, Kaslaris E, Kioussis D & Kollias G (1993). Wasting, ischaemia and lymphoid abnormalities in mice expressing T cell-targeted human tumour necrosis factor transgenes. *J. Immunol.* 151: 1894-1906.
64. Aloe L, **Probert L**, Kollias G, Bracci-Laudiero L, Micera A, Mollinari C & Levi-Montalcini R (1993). Level of nerve growth factor and distribution of mast cells in the synovium of tumour necrosis factor transgenic arthritic mice. *Int.J.Tissue Reactions* 15: 139-143.
65. Aloe L, **Probert L,** Kollias G, Bracci-Laudiero L, Spillantini MG & Levi-Montalcini R (1993). The synovium of transgenic arthritic mice expressing tumor necrosis factor contains a high level of nerve growth factor. *Growth Factors* 9: 149-155.
66. Keffer J, **Probert L**, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D & Kollias G (1991). Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. *EMBO J.* 10: 4025-4031. ***Selected as a classic paper in Rheumatoid Arthritis, PPS Europe Ltd, 1994**
67. **Probert L** & Hanley MR (1989). Still degrading after all these years. *Biochem.J.* 259: 621-622.
68. Anagnostides AA & **Probert L** (1989) The neuroendocrine system of the gut: a major field in modern gastroenterology. Hell. J. Gastroent. 2: 223-237.
69. **Probert L** & Hanley MR (1987). Immunocytochemical localisation of 'substance-P-degrading enzyme' within the rat spinal cord. Neurosci. Lett. 78: 132-137.
70. Bishop AE, Hodson NP, Major JH, **Probert L**, Yeats J, Edwards GB, Wright JA, Bloom SR & Polak JM (1984). The regulatory peptide system of the large bowel in equine grass sickness. *Experientia* 40: 801-806.
71. Tapia FJ, Varndell IM, **Probert L**, De Mey J & Polak JM (1983). Double immunogold staining method for the simultaneous ultrastructural localization of regulatory peptides. *J.Histochem.Cytochem.* 31: 977-981.
72. **Probert L**, De Mey J & Polak JM (1983). Demonstration of four different neuropeptides within ultrastructurally distinct subpopulations of p-type nerves in the guinea-pig colon by electron-immunocytochemistry. *Gastroenterology* 85: 1094-1104.
73. Gu J, Polak JM, **Probert L**, Islam KN, Marangos PJ, Mina S, Adrian TE, McGregor GP, O`Shaughnessy DJ & Bloom SR (1983). Peptidergic innervation of the human male genital tract. *J.Urol.* 130: 386-391.
74. Ferri G-L, Adrian TE, Ghatei MA, O`Shaughnessy DJ, **Probert L**, Lee YC, Polak JM & Bloom SR (1983). Tissue localisation and relative distribution of regulatory peptides in separated layers from the human bowel. *Gastroenterology* 84: 777-786.
75. Varndell IM, Tapia FJ, **Probert L**, Buchan AMJ, Gu J, De Mey J & Polak JM (1982). Immunogold staining method for the localisation of regulatory peptides. *Peptides* 3: 259-272.
76. Terenghi G, Polak JM, **Probert L**, McGregor GP, Ferri G-L, Blank MA, Butler JM, Unger WG, Zhang S, Cole DF & Bloom SR (1982). Mapping, quantitative distribution and origin of substance P- and VIP-containing nerves in the uvea of the guinea-pig eye. *Histochem.* 75: 399-417.
77. Hodson N, Edwards GB, Barnett SW, Bishop AE, Cole GA, **Probert L**, Bloom SR, Polak JM. (1982). Grass sickness of horses: changes in the regulatory peptide system of the bowel. *Vet. Rec.* 110: 276.
78. Ferri G-L, **Probert L**, Cocchia D, Michetti F, Marangos PJ & Polak JM (1982). The S-100 protein in the glial components of the human enteric nervous system. Nature 297: 409-410.
79. Bishop AE, Ferri G-L, **Probert L**, Bloom SR & Polak JM (1982). Peptidergic nerves. *Scand.J.Gastroenterol.* 17: 43-59.
80. Wharton J, Polak JM, **Probert L**, De Mey J, McGregor GP, Bryant MG & Bloom SR (1981). Peptide containing nerves in the ureter of the guinea-pig and cat. *Neuroscience* 6: 969-982.

81. **Probert L**, De Mey J & Polak JM (1981). Distinct subpopulations of enteric p-type neurones contain substance P and vasoactive intestinal polypeptide. *Nature* 294: 470-471.
82. Polak JM, Buchan AMJ, **Probert L**, Tapia F, De Mey J & Bloom SR (1981). Regulatory peptides in endocrine cells and autonomic nerves. Electron immunocytochemistry. *Scand.J.Gastroenterol.* 16: 11-23.
83. Thorndyke MC & **Probert L** (1979). Calcitonin-like cells in the pharynx of the ascidian Styela clava. *Cell Tiss.Res.* 203: 301-309.

INVITED CHAPTERS

1. Akassoglou K, Bauer J, Kassiotis G, Lassmann H, & **Probert L** (1999) Transgenic models of TNF-induced demyelination. In "Function of glial cells in health & disease: dialogue between glia and neurons" (eds R Matsas & M Tsacopoulos) Plenum Publishing Corporation.
2. Akassoglou K, Kassiotis G, Kollias G & **Probert L** (1998). Role for TNF in CNS inflammation, demyelination and neurodegeneration studied in transgenic mice. In "Neuroimmunodegeneration" (eds. PKY Wong, WS Lynn), Springer-Verlag and RG Landes Company, pp 135-154.
3. Kollias G, Corbella P, Dodou E, Georgopoulos S, Hislop S, Kazlaris E, Kioussis D, Pasparakis M & **Probert L** (1993). Transgenic models of tumor necrosis factor mediated disease. In, Tumor Necrosis Factor: Molecular and Cellular Biology and Clinical Relevance (eds. W Fiers & WA Buurman), Basel, Karger, pp 153-161.
4. Kollias G, Cazlaris H, Georgopoulos S, Kaslaris E, Keffer J, Kioussis D & **Probert L** (1992). Analysis of tumour necrosis factor gene expression and biological function in transgenic mice. In, Tumor Necrosis Factor: Structure-Function Relationship and Clinical Application (eds. T Osawa & B Bonavida), Basel, Karger, pp 159-165.
5. **Probert L** & Anagnostides AA (1991). The neuroendocrine system of the gut in inflammatory bowel disease. In, Inflammatory Bowel Disease (eds AA Anagnostides, HJF Hodgson and JB Kirsner), Chapman & Hall Medical, pp239-261.

PATENT APPLICATIONS

1. Methods of treating neurological diseases. EPO App. No. 13766804.2-1456 [US/10.09.12/ USP201261699230: US/23.05.13/ USP201361826922]. 10th May 2015.
2. Conjugates comprising mannan and myelin basic protein (MBP). USPO App. No. 14/877.679. 7th October 2015.
3. Therapeutic myelin sheath derived antagonistic peptide conjugates. EPO App. No. 14156495.5-1412 [GB/25.01.08/ GBA0801424: GB/08.02.08/ GBA 0802405: GR/29.02.08/ GRA 20080100151]. 22nd April 2014.
4. Therapeutic vaccines. Australia IP App. No. 2009207345, Ref. 147769. 11th October 2013.
5. Therapeutic myelin sheath derived antagonistic peptide conjugates. USPTO App. No. 12864019 [2011/0243981]. 28th October 2010.

TRANSGENIC MOUSE DISEASE MODELS DEVELOPED

Mouse name	Phenotype	Reference
Tg1278 huTNF (regulated huTNF expression)	normal	Keffer et al (1991) *EMBO J.* 10:4025
Tg197 huTNF-globin (huTNF in synoviocytes)	rheumatoid arthritis	Keffer et al (1991) *EMBO J.* 10:4025
Tg7 CD2-huTNF	normal	Probert et al (1993) *J. Immun.*151:1894

(huTNF in T cells)		
Tg211 CD2-huTNF-globin (huTNF in T cells)	cachexia/ septic shock	Probert et al (1993) *J. Immun.*151:1894
Tg6074 muTNF-globin (muTNF in oligos)	multiple sclerosis	Probert et al (1995) *PNAS USA* 92:11294 Akassoglou et al (1998) *AJP* 153: 801
TgK21 GFAP-huTNFΔ1-12-globin (tm huTNF in astrocytes)	multiple sclerosis CMT	Akassoglou et al (1997) *J.Immun.*158: 438 Akassoglou et al (1998) *Am.J.Path*. 153: 801
TgK742 NFL-huTNF-globin (huTNF in neurons)	encephalitis	Akassoglou et al (1997) *J.Immun.*158: 438
TgK3, TgK11, TgK14 NFL-huTNFΔ1-12-globin (tm huTNF in neurons)	normal	Akassoglou et al (1997) *J.Immun.*158: 438
Tg36 CD2-huFLIPL (huFLIP in T cells)	normal	Tseveleki et al (2004) *J.Immun.*173: 6619
Tg6988 NFL-muFLIP-IRES-EGFP (muFLIP in neurons)	normal	Taoufik et al (2007) J Neurosci. 27: 6633
Tg4617 NFL-dnIκB-IRES-EGFP (dnIκB in neurons)	normal	Casals et al, submitted for publication 2014.
TgMac1-Cre (Cre recombinase in myeloid-type cells)	normal	Evangelidou et al (2014) *J Immunol.* Epub 2014 Mar 28.

CONFERENCE PROCEEDINGS

1. Papazian I, Tsoukala E, Boutou A, Iliopoulou L, Probert L. Neuronal TNFR1 signaling plays an acute disease-promoting role in experimental MS models in vivo. The 14th ISNI Congress, Brisbane, Australia, 27-31 August, 2018 (selected for oral presentation).
2. Karamita M, Nicholas R, Papazian E, Avlonitou M, Mitsikostas D, Probert L, Papadopoulos D. Age and chronicity of demyelination determine motor impairment in a model of multiple sclerosis. The 34th Congress of ECTRIMS, Berlin, Germany, 10-12 October, 2018.
3. Kokoti L, Karamita M, Nicholas R, Mitsikostas DD, Probert L, Papadopoulos D. MS and CNS inflammatory disease: cellular senescence correlates with demyelination, brain atrophy and motor impairment in a model of multiple sclerosis. The sixth scientific forum: from Los Angeles to Syros, Syros Island, Greece, 25-27 May, 2018 (invited talk).
4. Boutou A, Papazian I, Iliopoulou L. The contributions of neuronal TNFR1 and TNFR2 to inflammatory demyelination in experimental models of multiple sclerosis. The 27th Hellenic Society for Neurosciences, Athens, Greece, 7-8 December, 2017 (selected for oral presentation).
5. Avloniti M, Evangelidou M, Dagkonaki A, Tselios T, Torp Jensen L, Probert L. Mannan-conjugated myelin peptides induce T cell anergy and treat multiple sclerosis-type disease in humanized DR2 mice. The 27th Hellenic Society for Neurosciences, Athens, Greece, 7-8 December, 2017 (poster).
6. Dagkonaki A, Evangelidou M, Avloniti M, Xenias P, Tselios T, Probert L. Protection against EAE by mannan-conjugated myelin peptides involves T cell anergy characterized by reduced antigen-specific proliferation and but not altered migration of T cells to the CNS. The 27th Hellenic Society for Neurosciences, Athens, Greece, 7-8 December, 2017 (poster).
7. Karamita M, Papadopoulos D, Mitsikostas DD, Gorgoulis V, Probert L, Nicholas R. Axonal damage and motor impairment correlate with glial cell senescence in a model of multiple sclerosis. The seventh joint ECTRIMS ACTRIMS meeting, Paris, France, October 25-28, 2017.
8. Boutou A, Karamita M, Szymkowski D, Lassmann H, Probert L. Inhibition of soluble TNF promotes remyelination by increasing myelin phagocytosis by CNS macrophages. The 16th ESNI Course, Venice, June 26-30, 2017 (selected for video presentation).
9. Dagkonaki A, Evangelidou M, Xenias P, Avloniti M, Tselios T, Probert L. Protection against EAE by mannan-conjugated myelin peptides involves T cell anergy characterized by reduced antigen-specific proliferation and but not altered migration of T cells to the CNS. The 16th ESNI Course, Venice, June 26-30, 2017 (selected for oral presentation).
10. Papazian I, Boutou A, Fisher R, Kontermann, Probert L. Dissecting the cellular and molecular requirements for TNF-mediated neuroprotection against glutamate excitotoxicity. The 16th ESNI Course, Venice, June 26-30, 2017 (selected for oral presentation).
11. Probert L. Towards humanized models for multiple sclerosis. Transgenic technologies in modeling human diseases: principles, associated technologies, animal management and ethics. June 5-13, 2017 (invited talk).
12. Kokoti L, Papadopoulos D, Karamita M, Mitsikostas DD, Gorgoulis V, Probert L, Nicholas R. Accelerated cellular senescence in a model of multiple sclerosis. The Fifth Scientific Forum: From Boston to Syros, Greece, June 2-4, 2017 (invited talk).
13. Papadopoulos D, Karamita M, Mitsikostas DD, Gorgoulis V, Probert L, Nicholas R. Accelerated cellular senescence in a model of multiple sclerosis. The 69th Annual Meeting of the American Academy of Neurology, April 22-28, 2017, Boston, MA (selected for oral presentation).

14. Probert L. Animal models for multiple sclerosis. The 3rd Panhellenic Meeting of the Hellenic Academy of Neuroimmunology for Multiple Sclerosis, Athens, November 19-22, 2015 (invited talk).
15. Papazian I, Probert L. Definition of the cellular and molecular mechanisms of TNF-mediated neuroprotection against glutamate excitotoxicity. The 3rd Panhellenic Meeting of the Hellenic Academy of Neuroimmunology for Multiple Sclerosis, Athens, November 19-22, 2015 (poster).
16. Evangelidou M, Karamita M, Szymkowski D, Probert L. Altered expression of oligodendrocyte and neuronal marker genes predicts the clinical onset of autoimmune encephalomyelitis and indicates the effectiveness of multiple sclerosis-directed therapeutics. The 3rd Panhellenic Meeting of the Hellenic Academy of Neuroimmunology for Multiple Sclerosis, Athens, November 19-22, 2015 (poster, awarded best poster prize).
17. Karamita M, Symkowski D, Tansey MJ, Probert L. Pre-clinical evaluation of a selective inhibitor of soluble TNF in a mouse model of progressive multiple sclerosis. The 3rd Panhellenic Meeting of the Hellenic Academy of Neuroimmunology for Multiple Sclerosis, Athens, November 19-22, 2015 (poster).
18. Probert L. Animal models of neuroinflammatory diseases: strengths and weaknesses. International Joint Israel-Greek-Italian Neuroimmunological Meeting, Elounda, Crete, 11-14 June 2015 (invited talk).
19. Probert L. Animal models of neuroinflammatory diseases: strengths and weaknesses. The 15th ESNI Course, Prague, Czech Republic, June 1-4, 2015 (invited talk).
20. Karamita M, Barnum CJ, Tesi RJ, Symkowski D, Tansey M, Probert L. Pre-clinical evaluation of a selective inhibitor of soluble TNF for treatment of chronic neuroinflammatory diseases. The 15th ESNI Course, Prague, Czech Republic, June 1-4, 2015.
21. Papazian I, Probert L. Dissecting the cellular and molecular requirements for TNF-mediated neuroprotection against glutamate excitotoxicity. The 15th ESNI Course, Prague, Czech Republic, June 1-4, 2015.
22. Probert L. Animal models for multiple sclerosis. The 3rd Scientific Forum: From Washington to Porto Heli, Porto Heli, Greece, May 29- June 1, 2015 (invited talk).
23. Papazian I & Probert L. Dissecting the cellular and molecular requirements for TNF-mediated neuroprotection against glutamate excitotoxicity. The 15th International Conference: Tumor Necrosis Factor, Ghent, Belgium, May 20-23, 2015 (poster).
24. Karamita M, Barnum C, Tesi R, Symkowski D, Tansey M, Probert L. Inhibition of soluble TNF protects mice against brain inflammation and demyelination in a cuprizone model for multiple sclerosis. The 12th International Congress of Neuroimmunology (ISNI), Mainz, Germany, 9-13 November, 2014 (poster, selected for oral presentation).
25. Kyrargyri V, Vega-Flores G, Gruart A, Delgado-Garcia JM, Probert L. Differential contributions of microglial and neuronal IKKβ in synaptic plasticity and associative learning in mice. The 12th International Congress of Neuroimmunology (ISNI), Mainz, Germany, 9-13 November, 2014 (poster, selected for oral presentation).
26. Papazian I. Study of phenotypic changes in cortical neuron cultures induced by mesenchymal stem cells medium during neuroprotection against glutamate-induced cell death. The 12th International Congress of Neuroimmunology (ISNI), Mainz, Germany, 9-13 November, 2014 (poster).
27. Award Ceremony in honor of Professor Hans Lassmann entitled “Disease mechanisms in multiple sclerosis”. The 2nd Congress of the Hellenic Academy of Neuroimmunology (HELANI), Thessaloniki, October 16-19, 2014.
28. Karamita M, Barnum CJ, Tesi RJ, Symkowski DE, Tansey MG, Probert L. Inhibition of soluble TNF protects mice against brain inflammation and demyelination in a cuprizone model for multiple sclerosis. New York Academy Science Meeting: Demyelination & Remyelination: From Mechanism to Therapy, New York, 26 June, 2014.

29. Probert L. Animal models for multiple sclerosis. The 2nd Scientific Forum: From Philadelphia to Porto Heli, Porto Heli, Greece, June 13-15, 2014 (invited talk).
30. Karamita M, Probert L. Interactions between neuroinflammation, demyelination and axon damage in a mouse model for chronic multiple sclerosis. Joint Meeting of the Hellenic Society for Neurosciences and EC REGPOT Capacities Project NeuroSign, November 29- December 1, 2013 (poster, selected for oral presentation).
31. Award Ceremony in honor of Professor Hartmut Wekerle entitled "T cells in Multiple Sclerosis: From basic immunology to therapy". The 1st Congress of the Hellenic Academy of Neuroimmunology (HELANI), Athens, October 18-20, 2013.
32. Voulgari-Kokota A, Papazian I, Evangelidou M, Kyrargyri V, Karamita M, Probert L. The neuroprotective effect of bone marrow mesenchymal stem cells on primary mouse neuronal cultures implicates the maintenance of progenitor cells and the upregulation of genes implicated in development. The 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS), Copenhagen, Denmark, October 2-5, 2013.
33. Probert L, Karamita M, Barnum CJ, Tesi RJ, Symkowski DE, Tansey MG. Inhibition of soluble TNF protects mice against brain inflammation and neurodegeneration in a cuprizone model for multiple sclerosis. The 14th International TNF Conference, Quebec City, Canada, July 7-10, 2013 (poster presentation).
34. Probert L. Neuronal control of CNS inflammation. The Joint Israeli-Greek Neuroimmunological Meeting 2012, Porto Carras Hotel, Chalkidiki, Greece, June 29-July 2, 2012 (invited talk).
35. Tseveleki V, Tselios T, Koursoni O, Friligou I, Emmanouil M, Katsara M, Vamvakas S-S, Apostolopulos V, Dotsika E, Matsoukas J, Lassmann H, Probert L. Immunotherapy of experimental autoimmune encephalomyelitis using APC-targeted myelin peptides as prophylactic and therapeutic vaccines. The 11th International Congress of Neuroimmunology (ISNI), Boston, Massachusetts, USA, November 4-8, 2012.
36. Probert L. De-sensitization of the immune system for therapy in multiple sclerosis. The 62nd Meeting of the Hellenic Society for Biochemistry & Molecular Biology, Athens, Greece, December 2011 (plenary lecture).
37. Karamita M, Probert L. The effect of neuronal IKKβ upon brain expression of inflammatory, myelin and neuronal genes during cuprizone-induced demyelination. The 62nd Meeting of the Hellenic Society for Biochemistry & Molecular Biology, Athens, Greece, December 2011 (selected for oral presentation).
38. Kyrargyri V, Sebastiao A-M, Probert L. Role of neuronal IKKβ in synaptic plasticity and homeostatic synaptic scaling. The 62nd Meeting of the Hellenic Society for Biochemistry & Molecular Biology, Athens, Greece, December 2011 (poster presentation).
39. Probert L. Re-establishing peripheral tolerance to CNS antigens for therapy in multiple sclerosis. Discussions between Greek Neuroscientists on Multiple Sclerosis", Hotel Cape Sounio, Attiki, Greece, September 30- October 2, 2011 (invited talk).
40. Probert L. Eighth International Brain Research Organization World Congress of Neuroscience, Florence, Italy, July 14-18, 2011.
41. Karamita M, Probert L. The effect of neuronal IKK2 upon brain expression of inflammatory, myelin and neuronal genes during cuprizone-induced demyelination. Eleventh ESNI Course, Glasgow, UK, July 4-7, 2011 (selected for oral presentation).
42. Kyrargyri V, Probert L, Sebastiao AM. Role of neuronal IKK2 in synaptic plasticity and homeostatic synaptic scaling. Eleventh ESNI Course, Glasgow, UK, July 4-7, 2011 (poster presentation).
43. Probert L. Final Meeting of Management Committee and Working Groups COST Action BM0603 "Neurinfnet", Dublin, Ireland, June 2011 (member of management committee).
44. Probert L. Tuning TNF as a target for therapy in CNS inflammation. Seventh Aegean Meeting on Neurological Therapeutics, Capsis Convention Centre, Heraklion, Crete, May 27-28, 2011 (invited talk).

45. Taoufik E, Tseveleki V, Lassmann H, Szymkowski D, Probert L. Selective blockade of soluble tumour necrosis factor signaling ameliorates experimental autoimmune encephalomyelitis in mice. Tenth International Congress of Neuroimmunology (ISNI), Sitges, Barcelona, Spain, October 2010 (selected for oral presentation). J. Neuroimmunol. 2010; 228 (1-2): abstract 599.
46. Taoufik E, Kang T-B, Wallach D, Probert L. Caspase 8 mediates neuron death following in vivo and in vitro excitotoxic injury. Tenth International Congress of Neuroimmunology, Sitges, Barcelona, Spain, October 2010 (selected for oral presentation). J. Neuroimmunol. 2010; 228 (1-2): abstract 600.
47. Probert L. The Brain: Function, Imaging & Repair. Second International Workshop, Gaia Centre, Kifissia, Greece, 19-21 October 2009.
48. Probert L. Neuronal control of brain inflammation. Ninth ESNI Course, Istanbul, Turkey, September 2009 (invited talk).
49. Probert L. Role of the neuronal TNFRI/ NF-κB signaling axis in the maintenance of CNS immune privilege and neuroprotection. NeuroproMiSe International Workshop, New developments in multiple sclerosis research, Groningen, Netherlands, June 2009 (invited talk).
50. Karamita M, Taoufik E, Evangelidou M, Ladopoulou A, Boulikas T, Probert L, Roberts ML (2009). Development of a novel liposome formulation for the in vivo delivery of nucleic acids to the CNS. Twelfth Annual Meeting of the American Society of Gene Therapy, San Diego, CA, USA, May 2009. Molecular Therapy 17 (suppl1): S58.
51. Manoloukos M, Tseveleki V, Katsoupi P, Probert L, Boulikas T, Roberts ML (2009). Development of alphaviral vectors for the delivery of short-hairpin RNA. Twelfth Annual Meeting of the American Society of Gene Therapy, San Diego, CA, USA, May 2009. Molecular Therapy 17 (suppl1): S58.
52. Evangelidou M, Tseveleki V, Vamvakas S-S, Probert L. Role of TNFRI as a costimulatory molecule during the early phase of TCR stimulation in CD3 T lymphocytes. Twelfth TNF Conference, Madrid, Spain, April 26-29, 2009 (poster presentation, M Evangelidou).
53. Emmanouil M, Taoufik E, Tseveleki V, Vamvakas S-S, Evangelidou M, Karin M, Lassmann H, Probert L. Neuronal NF-κB (IKKβ) suppresses neuroinflammation and protects against neurological deficits in demyelinating CNS disease. Twelfth TNF Conference, Madrid, Spain, April 26-29, 2009 (oral presentation, M Emmanouil).
54. Taoufik E, Kang T-B, Wallach D, Probert L. Caspase 8 mediates neuron death following *in vivo* and *in vitro* excitotoxic injury. Twelfth TNF Conference, Madrid, Spain, April 26-29, 2009 (oral presentation, E Taoufik).
55. Oikonomou E, Psahoulia F, Kosmidou V, Taoufik E, Probert L, Andera L, Pintzas A. TRAIL induced cell death in colon carcinoma cells in vivo and in vitro: sensitization by oncogenes and by other therapeutics. Twelfth TNF Conference, Madrid, Spain, April 26-29, 2009.
56. Evangelidou M, Tseveleki V, Probert L. The role of TNFR1 as a costimulatory molecule during the early phase of TCR stimulation in CD3 T lymphocytes. NeuroproMiSe International Workshop, CD8 T cells in central nervous system inflammation, Rome, Italy, March 5-6, 2009 (poster presentation, M Evangelidou).
57. Tseveleki V, Tselios T, Friligou I, Emmanouil M, Katsara M, Evangelidou M, Matsoukas J, Lassmann H, Apostolopoulos V, Probert L. Immunotherapy of experimental autoimmune encephalomyelitis using novel mannosylated peptides in therapeutic and prophylactic vaccination protocols. Keystone Symposia: Multiple Sclerosis, Santa Fe, New Mexico, January 2009 (poster presentation, V Tseveleki).
58. Probert L. Workshop on CNS Inflammation and Third NeuroproMiSe General Meeting. Toulouse, France, November 3-5, 2008.
59. Emmanouil M, Taoufik E, Tseveleki V, Tselios T, Karin M, Lassmann H, Probert L. Dissection of the cell-specific functions of NF-κB in experimental autoimmune

encephalomyelitis. Ninth International Congress of Neuroimmunology (ISNI), Fort Worth, Texas, USA, October 26-30, 2008 (poster presentation, M Emmanouil).

60. Voulgari-Kokota A, Delorme B, Taoufik E, Tseveleki V, Charbord P, Probert L. Bone marrow mesenchymal stem cells protect neurons from excitotoxic death. Nineth International Congress of Neuroimmunology (ISNI), Fort Worth, Texas, USA, October 26-30, 2008 (poster presentation, A Voulgari-Kokota).
61. Emmanouil M, Taoufik E, Tseveleki V, Tselios T, Karin M, Lassmann H, Probert L. Dissection of the cell-specific functions of NF-κB in experimental autoimmune encephalomyelitis. EMBO Workshop on NF-κB in development and disease, Capri, Italy, October 2008 (oral presentation, M Emmanouil).
62. Voulgari-Kokota A, Delorme B, Taoufik E, Tseveleki V, Charbord P, Probert L. Bone marrow mesenchymal stem cells protect neurons from excitotoxic death. Twenty-second Annual Meeting of the Hellenic Society for Neuroscience, Athens, Greece, October 16-19, 2008 (Poster presentation, A Voulgari-Kokota).
63. Probert L, Taoufik E, Emmanouil M, Tseveleki V, Voulgari-Kokota A, Evagelidou M. Role of neuronal TNF ligand/receptor signalling axis in the maintenance of CNS immune privilege and neuroprotection Twenty-second Annual Meeting of the Hellenic Society for Neuroscience, Athens, Greece, October 16-19, 2008 (invited talk, L Probert).
64. Voulgari-Kokota A, Delorme B, Taoufik E, Charbord P, Probert L. Study of mesenchymal stem cell neuroprotective function and the implication of TNF/TNFRI signaling. ESH-EHA Scientific Workshop Biology and Clinical Applications of Mesenchymal Stem Cells, Mandelieu, France, July 2008 (Poster presentation, A Voulgari-Kokota).
65. Probert L. Autoimmune neurodegenerative syndromes. Hellenic Research Foundation Workshop- Recent Advances in the Pathophysiology and Treatment of Neurodegenerative Diseases, Athens Greece, June 13, 2008 (invited talk).
66. Probert L. Neuronal Control of Myelination. Gordon Research Conference Myelin, Il Ciocco, Italy, May 2008.
67. Beina S, Emmanouil M, Taoufik E, Tselios T, Flavell R, Karin M, Probert L. Study of the cell-specific functions of transcription factor NF-κB activation in the central nervous system during experimental autoimmune encephalomyelitis. Thirtieth Conference of Hellenic Society of Biologists (EEBE), Thessaloniki, Greece, May 2008 (oral and poster presentation, S Beina).
68. Manta A, Evangelidou M, Margaritis LX, Probert L. Study of the role of caspase 8 in the activation of T lymphocytes through the TCR. Thirtieth Conference of Hellenic Society of Biologists (EEBE), Thessaloniki, Greece, May 2008 (oral & poster presentation, A Manta).
69. Voulgari-Kokota A. The 7th European School of Neuroimmunology (ESNI) Course, Oxford, UK, September 20-23, 2007.
70. Koutrolos M, Emmanouil M, Haralambous S, Tselios T, Probert L. Role of neuron-specific human transmembrane TNF in the CNS during experimental autoimmune encephalomyelitias in mice. Twenty-ninth Meeting of Hellenic Society of Biologists (EEBE), Kavala, Greece, May 2007 (oral & poster presentation, M Koutrolos).
71. Emmanouil M, Taoufik E, Tseveleki V, Karin M, Lassmann H, Probert L. Selective inhibition of NF-κB in CNS neurons exacerbates experimental autoimmune encephalomyelitis in mice. Eleventh International TNF Conference, Pacific Grove, CA, USA, May 2007 (Poster presentation, M Emmanouil).
72. Euagelidou M, Chatzidakis Y, Tseveleki V, Tsangaris G, Probert L. Effect of TNFRI on protein expression in TCR stimulated CD3 T lymphocytes. Eleventh International TNF Conference, Pacific Grove, CA, USA, May 2007 (selected for oral presentation, M Euagelidou).
73. Taoufik E, Valable S, Muller G, Roberts ML, Divoux D, Tinel A, Voulgari-Kokota A, Tseveleki V, Altruda F, Lassmann H, Petit E, Probert L. $FLIP_L$ protects against ischemia-

induced neuronal death. Eleventh International TNF Conference, Pacific Grove, CA, USA, May 2007 (Poster presentation, E Taoufik).

74. Taoufik E, Mengozzi M, Tseveleki V, Ghezzi P, Cerami A, Brines M, Probert L. EPO mediated neuroprotection against ischemic and excitotoxic injury requires TNFRI signaling. Eleventh International TNF Conference, Pacific Grove, CA, USA, May 2007 (Poster presentation, E Taoufik).
75. Tseveleki V, Rubio R, Ahumada A, Taoufik E, Simos N, Quackenbush J, Probert L. Gene expression profiling of CNS diseases in mouse models for discovery of pathogenic pathways and tissue defence responses. Eleventh International TNF Conference, Pacific Grove, CA, USA, May 2007 (Poster presentation, V Tseveleki).
76. Tseveleki V, Tsagozis P, Ntotsika E, Probert L. Cellular FLIP long isoform transgenic mice overcome inherent Th2-biased immune responses to efficiently resolve *Leishmania major* infection. Eleventh International TNF Conference, Pacific Grove, CA, USA, May 2007 (Poster presentation, V Tseveleki).
77. Probert L. Death receptor signaling pathways control neuron fate following ischemic injury. COST Action B30, Nereplas, First Meeting, Carmona, Spain, November 2006 (invited presentation).
78. Taoufik E, Valable S, Muller GJ, Tinel A, Plows D, Divoux D, Roberts ML, Tseveleki V, Lassmann H, Petit E, Probert L. Neuroprotective role of FLIP: implications for MS. First NeuroproMiSe Meeting, Rome, Italy, November 6, 2006 (Poster presentation, E taoufik).
79. Taoufik E, Mengozzi M, Tseveleki V, Brines M, Ghezzi P, Cerami A, Probert L. EPO mediated neuroprotection against ischemic and excitotoxic injury requires TNFRI signaling. Eighth International Congress of Neuroimmunology (ISNI), Nagoya, Japan, October 2006 (selected for oral presentation, E Taoufik).
80. Tseveleki V, Tsagozis P, Dotsika E, Probert L. Cellular FLIP long isoform transgenic mice overcome inherent Th2-biased immune responses to efficiently resolve Leishmania major infection. Sixteenth European Congress of Immunology (EFIS), Paris, France, September 2006.
81. Taoufik E, Mengozzi M, Tseveleki V, Ghezzi P, Cerami A, Brines M, Probert L. TNF receptor I protects cortical and hippocampal neurons from ischemic and excitotoxic injury by inducing EPO and EPO receptor expression. Fourth International Symposium on Neuroprotection and Neurorepair, Magdeburg, Germany, May 2006 (selected for oral presentation, E Taoufik).
82. Probert L. Seventh Conference of Medicinal Chemistry: Drug Discovery and Design, University of Patras, Departments of Chemistry & Pharmacy, March 8-11, 2006.
83. Probert L. Protein Misfolding Diseases: Mechanisms of Misfolding, Pathology and Therapeutic Strategies. Keystone symposium, Breckenridge, Colorado, February 2006.
84. Probert L. Immunoregulation of Th1 and Th2 responses in neuroinflammation. Sixth European School of Neuroimmunology Course, Thessaloniki, Greece, September 12-15, 2005 (invited talk).
85. Emmanouil M, Tseveleki V, Probert L. Conditional targeting of the IKKβ gene in mice as an approach for determining the cellular basis of EAE modulation by myelin peptide analogues and a strategy for the development of a peptide vaccine for multiple sclerosis. Sixth Conference of Medicinal Chemistry: Drug Discovery and Design, University of Patras, Departments of Chemistry & Pharmacy, March 10-12, 2005 (oral presentation M. Emmanouil).
86. Taoufik E, Valable S, Muller GJ, Tinel A, Plows D, Divoux D, Roberts ML, Tseveleki V, Lassmann H, Petit E, Probert L. Death receptor signaling pathways control neuron fate following ischemic injury. Keystone Symposia: Cellular Senescence and Cell Death, Keystone, Colorado, March 2005 (poster presentation, E Taoufik).
87. Probert L. Symposium Organizer and Chairperson- Signalling Mechanisms in Brain Inflammation (co-chaired with Dr Jon Sedgwick, Eli Lilly Co., CA, USA). The 7th

International Congress of Neuroimmunology (ISNI), Venice, Italy, September 28-October 2, 2004.

88. Probert L. Death receptor signaling pathways control neuron fate following ischemic injury. Seventh International Congress of Neuroimmunology, Venice, Italy, September 28- October 2, 2004 (replacement talk for Dr Mark Mattson).
89. Taoufik E, Valable S, Muller GJ, Tinel A, Plows D, Divoux D, Roberts ML, Tseveleki V, Lassmann H, Petit E, Probert L. Death receptor signaling pathways control neuron fate following ischemic injury. The 10th TNF Superfamily Conference. Lausanne, Switzerland, September 2004 (poster presentation, E Taoufik).
90. Probert L. Visualisation of proliferative and cytotoxic mechanisms induced by TNF in transgenic mice as a means for understanding the development of inflammatory lesions. Educational Seminars in Science & Technology "Applications of Methodology in Light Microscopy in Biomedical Research and Diagnosis". Hellenic Pasteur Institute, May 2004 (invited talk).
91. Tseveleki V, Voulgari-Kokota A, Probert L. Selective immuno-regulation in autoimmune model for multiple sclerosis through modulation of antigen-specific T cells. The 6th Conference of Medicinal Chemistry: Drug Discovery and Design, University of Patras, Departments of Chemistry & Pharmacy, March 2004 (V. Tseveleki, oral presentation).
92. Tseveleki V, Bauer J, Taoufik E, Ruan C, Haralambous S, Lassmann H & Probert L. Immunoregulatory role of c-$FLIP_L$ in T lymphocytes. Keystone Symposia: Regulatory/ Suppressor T Cells, Banff, Canada, March 2004 (selected for oral presentation, V Tseveleki).
93. Haralambous S. Course participant "Cytopreservation of mouse germplasm" Monterotondo Scalo, Rome, Italy, November 6-7, 2003.
94. Tseveleki V. Course participant in International Flow Cytometry School "Antigen Specific T Cell Flow Cytometry", Munich, Germany, September 2003.
95. Probert L. Symposium Organizer and Chairperson- Neurodegeneration and Immunoregulation (co-chaired with Prof. Nils Gilhus, Oslo, Norway). The 4th European School of Neuroimmunology (ESNI) Course, Barcelona, Spain, September 2003.
96. Taoufik E. Immunoregulatory mechanisms in neuroprotection. The 4th European School of Neuroimmunology (ESNI) Course, Barcelona, Spain, September 2003 (invited talk).
97. Argyros O, Tseveleki V, Bauer J, Taoufik E, van Roojen N, Lassmann H, Probert L. Functional dissociation of the central and peripheral effects of TNF in the development of CNS inflammation and demyelination in transgenic mice. Fourth European School of Neuroimmunology Course, Barcelona, Spain, September 2003 (poster presentation, O Argyros).
98. Tseveleki V, Taoufik E, Probert L. Attendance to European Immunology Conference, Rhodos, Greece, May 8-12, 2003.
99. Taoufik E, Petit E, Tseveleki V, Plows D, Divoux D, Muller G, Lassmann H, Probert L. TNF/p55TNFR signaling mediates neuroprotection in a mouse model of cerebral ischemia through the activation of NF-κB and the regulation of critical target genes. Third International Symposium on Neuroprotection & Neurorepair, Magdeburg, Germany, May 2003 (poster presentation, E Taoufik).
100. Probert L. Animal Models in Understanding Autoimmune Diseases. Fourth Conference of Medicinal Chemistry: Drug Discovery and Design, University of Patras, Departments of Chemistry & Pharmacy, March 2003 (invited talk).
101. Taoufik E, Petit E, Tseveleki V, Plows D, Divoux D, Muller G, Lassmann H, Probert L. Neuroprotective effects of TNF/p55TNFR signaling in vivo following experimental ischaemia are mediated by NF-kappaB. Ninth TNF Superfamily Congress, San Diego, USA, October 2002 (abstract selected for oral presentation, E Taoufik).
102. Probert L. Cytokine mediated brain damage. Third European School of Neuroimmunology Course, Tampere, Finland, September 11-14, 2002 (invited talk).

103. Tseveleki V, Ruan C, Plows D, Taoufik E, Haralambous S & Probert L. Probing the *in vivo* function of FLIP in T lymphocytes. FEBS International Summer School on Immunology, "The Immune System: Genes, Receptors and Regulation". Ionian Village, Peloponnese, Greece, September 2002 (course participant and poster presentation, V Tseveleki).
104. Tseveleki V & Probert L. Gene expression profiling used for analysis of genotype-phenotype interrelationships in a mouse model for multiple sclerosis. Fifth European Meeting on Glial Cell Function in Health & Disease, Rome, Italy, May 2002 (poster presentation, V Tseveleki). Glia May 2002; S85-86 (suppl. 1), poster 336.
105. Akassoglou K, Bauer J, Tseveleki V, Lassmann H, Probert L, Strickland S. Fibrin induces inflammation and inhibits recruitment of oligodendrocyte progenitors in a transgenic animal model of multiple sclerosis. Fifth European Meeting on Glial Cell Function in Health & Disease, Rome, Italy, May 2002 (poster presentation, K Akassoglou). Glia suppl. 1, May 2002, S81.
106. Probert L. Animal Models in Understanding Autoimmune Diseases. Third Conference of Medicinal Chemistry: Drug Discovery and Design,University of Patras, Departments of Chemistry & Pharmacy, March 2002 (invited talk).
107. Probert L. Role of the TNF receptor family in cell death & survival in the CNS. FEBS Advanced Course "From Differentiation to Death of Nerve Cells". Spetses, Greece, September 2001 (invited talk).
108. Taoufik E, Petit E, Lassmann H & Probert L. Cellular basis of TNF-mediated neuroprotection. Sixth International Congress of Neuroimmunology, Edinburgh, Scotland, September 2001 (poster presentation, E Taoufik). J Neuroimmunol. 118: 32.
109. Taoufik E. Course participant EMBO practical course "Mouse Genome Engineering by Site-Specific recombinases" Braunschweig, Germany, September 2001.
110. Tseveleki V. Course participant EMBO practical course "DNA Microarrays: Applications and Data Analysis", Heidelberg, Germany, September 2001.
111. Probert L. The role of TNF in experimental autoimmune encephalomyelitis/ multiple sclerosis: modeling of disease mechanisms and therapeutic approaches in animals. Fourteenth National Conference of the Italian Immunology Society, Abano, Italy, June 6-9, 2001 (plenary lecture). Minerva Biotechnologica; J. Biotechnol. Mol. Biol. June 2001, 13 (3): 184.
112. Probert L. Transgenic Mice, Models for Human Disease, Educational Seminars "Modern Diagnostic Methods", Hellenic Pasteur Institute, Athens, April 2001 (invited seminar).
113. Probert L. Use of Animal Models for Understanding Multiple Sclerosis. Second Conference of Medicinal Chemistry: Drug Discovery and Design, University of Patras, Departments of Chemistry & Pharmacy, March 2001 (invited talk).
114. Akassoglou K, Kombrinck K, Salles F, Kollias G, Probert L, Degen J, Strickland S. Fibrin deposition exacerbates axonal damage. Thirtyth Annual Meeting of Society for Neuroscience, New Orleans, USA, November 2000 (oral presentation, K Akassoglou)..
115. Probert L. Cross-talk between the immune and the nervous system: role of TNF in glial cell function and implications for pathology. Fifteenth Annual Meeting of the Hellenic Society for Neuroscience, Patras, October 2000 (invited talk).
116. Akassoglou K, Kollias G, Probert L, Strickland S. Fibrin deposition correlates with axonal damage and demyelination in a transgenic animal model of multiple sclerosis. 15th International Congress on Fibrinolysis and Proteolysis, Hamamatsu, Japan, June 2000 (oral presentation, K Akassoglou).
117. Kassiotis G, Alexopoulou L, Probert L, Kollias G. Uncoupling the proinflammatory from the immunosuppressive properties of TNF in autoimmune demyelination: implications for disease pathogenesisi and therapy. Eighth TNF Congress on Tumor Necrosis Factor and Related Cytokines, Trondheim, Norway, May 2000 (poster presentation, G Kassiotis).

118. Kassiotis G, Alexopoulou L, Probert L, Kollias G (2000). TNF mediates regulation of myelin-directed T cell autoimmunity and protects non-susceptible backgrounds against EAE. Keystone Symposium, Tolerance and Autoimmunity, Keystone, Colorado. March 2000 (poster presentation, G Kassiotis).
119. Probert L (1999). EU Sectoral Meeting. CNG, Milan, Italy, October 13, 1999.
120. Tselios T, Dagliani I, Deraos S, Roumelioti P, Matsouka E, Probert L, Mavromoustakos T (1999). Design and synthesis of cyclic peptide (c-MBP72-85) of myelin basic protein: induction of experimental allergic encephalomyelitis (EAE). Sixth Chemistry Conference Greece-Cyprus: Chemistry and Qualitative Systems in Production and Testing, Rhodes, Greece, September 1999 (poster presentation, T Tselios).
121. Probert L (1999). TNF and its receptors in CNS Function: Friend and Foe. Institute of Medical Research, Budapest, Hungary, February 1999 (invited seminar).
122. Probert L (1999). Transgenic and Knockout Models of TNF-induced Inflammation and Demyelination", Neurological Clinic, University Hospital of Szeged, Hungary, February 1999 (invited seminar).
123. Probert L (1998). Transgenic and knockout models of TNF-induced inflammation and demyelination. Ares-Serono, Geneva, November 1998 (invited seminar).
124. Kassiotis G, Pasparakis M, Bauer J, Lassmann H, Probert L, Kollias G (1998). Investigation of TNF-targets in a TNF transgenic model for multiple sclerosis using a cell-specific gene targeting approach. Second Joint Meeting of the International Cytokine Society (ICS) and the International Society for Interferon & Cytokine Research (ISICR), Jerusalem, Israel, October 1998 (poster presentation, G Kassiotis). European Cytokine Network 9: 359.
125. Tselios T, Probert L, Kollias G, Daliani I, Matsoukas E, Roumelioti P, Alexopoulos K, Matsoukas J (1998). Synthesis of a novel cyclic analogue of the myelin basic protein epitope MBP72-85. Budapest, Hungary, September 1998 (invited talk, J Matsoukas).
126. Probert L, Akassoglou K, Kassiotis G, Bauer J, de Kozak Y, Lassmann H, Kollias G (1998). The TNF/TNF receptor system in CNS disease: studies in transgenic and mutant mice" 5th International Congress, International Society of Neuroimmunology, Montreal, Canada, August 23-27, 1998 (session chairperson and invited talk, L Probert). *J. Neuroimmunology* 90 (1): 9.
127. de Kozak Y, Thillaye-Goldenberg B, Akassoglou K, Kassiotis G, Keller N, Naud MC, Pasparakis M, Kollias G, Probert L (1998) Regulatory role of TNF in experimental ocular inflammation. 5th International Society of Neuroimmunology, Montreal, Canada, August 1998. *J. Neuroimmunology* 90 (1): 55 (poster presentation, L Probert).
128. Akassoglou K, Bauer J, Kassiotis G, Lassmann H, Kollias G & Probert L (1998) Local TNF ligand/receptor signaling induces MS-type plaques in the CNS of transgenic mice. 5th International Society of Neuroimmunology, Montreal, Canada, August 1998 (oral presentation, K Akassoglou). *J. Neuroimmunology* 90 (1): 46.
129. Kollias G, Akassoglou K, Kassiotis G & Probert L (1998) Molecular and cellular pathways of TNF action in the CNS: studies in transgenic and conditionally mutant mice. 13th International Congress of Pharmacology, Munich, July 1998 (invited speaker, G Kollias).
130. Kollias G, Akassoglou K, Kassiotis G & Probert L (1998) Transgenic and knockout models of TNF-induced CNS inflammation and demyelination. Invited speaker at the 1998 Forum of European Neuroscience, Berlin, June 1998 (invited speaker, G Kollias).
131. de Kozak Y, Akassoglou K, Kassiotis G, Thillaye-Goldenberg B, Pasparakis M, Keller N, Naud MC, Kollias G & Probert L (1998) Ocular inflammation in transgenic and knockout mice expressing glial-specific transmembrane TNF and in TNF knockout mice. First combined International Symposium on Ocular Immunology and Inflammation, Amsterdam, June 1998 (oral presentation, Y de Kojak).
132. de Kozak Y, Akassoglou K, Kassiotis G, Thillaye-Goldenberg B, Pasparakis M, Keller N, Naud MC, Kollias G & Probert L (1998) Local regulation of experimental ocular pathology

by cytokines: critical role of tumor necrosis alpha. Thirteenth International Congress of Eye Research, Paris 1998 (oral presentation, Y de Kojak).

133. Probert L, Akassoglou K, Kassiotis G & Kollias G. TNF and receptors in CNS function: Friend and Foe. Seventh International TNF Congress, Hyannis MA, May 1998 (invited speaker, L Probert). *J. Interferon & Cytokine Research* 18 (5): A-83.

134. Kassiotis G, Pasparakis M, Bauer J, Lassmann H, Probert L & Kollias G (1998) Study of TNF-induced oligodendrocyte pathology using a conditional gene targeting approach. Seventh International TNF Congress, Hyannis MA, USA, May 1998 (poster presentation, G Kassiotis). *J. Interferon & Cytokine Research* 18 (5): A-70.

135. de Kozak Y, Thillaye-Goldenberg B, Kassiotis G, Naud MC, Pasparakis M, Kollias G & Probert L (1998) TNF knockout mice show increased experimental autoimmune uveoretinitis induced by a retinal autoantigen. Seventh International TNF Congress, Hyannis MA, USA, May 1998 (poster presentation, Y de Kojak). *J. Interferon & Cytokine Research* 18 (5): A-92.

136. de Kozak Y, Akassoglou K, Naud MC, Keller N, Thillaye-Goldenberg B, Kollias G & Probert L (1998) Spontaneous ocular inflammation and optic nerve degeneration in transgenic mice expressing glial-specific but not neuron-specific transmembrane TNF. Seventh International TNF Congress, Hyannis MA, USA, May 1998 (poster presentation, Y de Kojak). *J. Interferon & Cytokine Research* 18 (5): A-92.

137. Akassoglou K, Pasparakis M, Bauer J, Lassmann H, Probert L & Kollias G (1998) Probing for the cellular specificity of the p55 TNFR in TNF-induced inflammatory demyelination: Conditional gene targeting of the p55 TNFR in astrocytes. Seventh International TNF Congress, Hyannis MA, USA, May 1998 (poster presentation, K Akassoglou). *J. Interferon & Cytokine Research* 18 (5): A-86.

138. Akassoglou K, Douni E, Bauer J, Lassmann H, Kollias G & Probert L (1998) Transmembrane TNF signaling through p75 TNFR induces inflammatory ischaemia in the CNS of transgenic mice. Seventh International TNF Congress, Hyannis MA, USA, May 1998 (selected for oral presentation). *J. Interferon & Cytokine Research* 18 (5): A-87.

139. Probert L, Akassoglou K, Kassiotis G & Kollias G (1998) Transgenic models of TNF-alpha induced demyelination. Third European Meeting on Glial Cell Function in Health and Disease; Dialogue between Glia and Neurons. Athens, Greece, May 1998 (invited speaker, L Probert).

140. Kontoyiannis D, Plows D, Kassiotis G, Probert L & Kollias G (1998) Role of the adaptive immune response in models of TNF-mediated pathologies. 1998 European Network of Immunology Institutes Conference, “Pathogenic and Protective T cell Responses”. Ile des Embiez, May, 1998 (invited speaker, G Kollias).

141. Akassoglou K, Kassiotis G, Kollias G & Probert L (1998) Local TNF/p55TNF receptor signaling in the CNS of transgenic mice models multiple sclerosis. Eighteenth European Workshop for Rheumatology Research. Athens, March 12-15, 1998 (selected for oral presentation, L Probert). *Clin. Exp. Rheumatology* 16 (2): 200. KA & GKa jointly awarded the “Young Investigator” prize.

142. Probert L, Akassoglou K, Kassiotis G, Bauer J, Lassmann H & Kollias G (1997) TNF-mediated CNS inflammation and demyelination models chronic and acute multiple sclerosis. International Symposium: Immunopathology of Multiple Sclerosis, University of Vienna, Austria, November 1997 (invited speaker, L Probert).

143. Kollias G, Akassoglou K, Alexopoulou L, Douni E, Haralambous S, Hill S, Kassiotis G, Kontoyiannis D, Pasparakis M, Plows D & Probert L (1997) Transgenic animals as a means to understanding diseases. EULAR ’97, Vienna, Austria, November, 1997 (invited speaker, G Kollias).

144. Akassoglou K, Probert L, Kollias G (1997). Applications of transgenic and knockout systems in the study of the pathology of the nervous system. Hellenic Society of Pathology & Pathological Anatomy: Basic Principles and Applications of Molecular Pathological Anatomy, Athens, October 1997 (oral presentation, K Akassoglou).

145. Akassoglou K, Kassiotis G, Kollias & Probert L (1997) Primary and destructive demyelination induced by the central nervous system production of TNF. Seventeenth Blankenese Conference on Neurodegeneration, Hamburg, Germany, July 1997 (selected for oral presentation, K Akassoglou).
146. Kassiotis G, Akassoglou K, Kollias G & Probert L (1997) TNF-triggered CNS inflammation, demyelination and T cell autoreactivity in transgenic mice: A role for mature lymphocytes in disease modulation but not disease initiation. Thirteenth European Immunology Meeting, Amsterdam, The Netherlands, June 22-25, 1997 (selected for oral presentation, L Probert). Immunology Letters 56 (1-3): 219.
147. Kassiotis G, Akassoglou K, Kollias G, Probert L (1997). TNF-triggered CNS inflammation, demyelination and T cell autoreactivity in transgenic mice: a role for mature lymphocytes in disease modulation but not disease initiation. EEBE Meeting of the Baltic Countries, Thessaloniki, Greece, May 1997 (poster presentation, G Kassiotis).
148. Kassiotis G, Akassoglou K, Pasparakis M, Kollias G & Probert L (1997) The role of TNF in both T cell and non T cell-triggered autoimmune events affecting the CNS. Keystone Symposium, Tolerance and Autoimmunity, Keystone, Colorado, April 1997 (selected for oral presentation, G Kassiotis).
149. Akassoglou K, Kassiotis G, Bauer J, Lassmann H, Kollias G & Probert L (1997) Primary and destructive demyelination induced by the central nervous system production of TNF in transgenic mice: TNF transgenic models for MS. Multiple Sclerosis: Frontiers in Science, and Patient Care & Disease Management, NEC, Birmingham, UK, March 1997 (poster presentation, L Probert). Received the "Best Poster Award: from The Multiple Sclerosis Society of Great Britain & Northern Ireland.
150. Tselios T, Deraos S, Matsouka E, Papayiotopoulos D, Alexopoulos K, Matsoukas J, Moore GJ, Probert L, Kollias G, Hillard B, Rostami A, Monos D (1996). Peptides of myelin basic protein: induction and amelioration of experimental allergic encephalomyelitis (EAE). Seventeenth Hellenic Chemistry Meeting, Patras, Greece, December 1996.
151. Kassiotis G, Akassoglou K, Kollias G & Probert L (1996) Autoimmune reactivity in a transgenic model of TNF alpha-triggered CNS inflammation and demyelination. First Joint Meeting of the International Cytokine Society (ICS)/International Society for Cytokine Research (ISICR), Geneva, Switzerland, October 6-10, 1996. *Eur. Cyt. Netw*. 7 (3): 461 (selected for oral presentation, L Probert).
152. Alonzi T, Fattori E, Costa P, Lazzaro D, Probert L, Kollias G, Ciliberto G & Poli V (1996) Correlations between IL-6 and arthritis: development of different murine models. First Joint Meeting of the International Cytokine Society (ICS)/International Society for Cytokine Research (ISICR), Geneva, Switzerland, October 1996. *Eur. Cyt. Netw*. 7 (3): 560.
153. Bessis N, Kollias G, Probert L, Caput D, Fournier C, Fradelizi D & Boissier MC (1996) Treatment of TNF transgenic mice by systemic gene therapy with Th2 cytokines decreases TNF transgene expression. Sixtieth National Scientific Meeting of the American College of Rheumatology, Orlando, Florida, October 1996.
154. Alonzi T, Fattori E, Costa P, Lazzaro D, Probert L, Kollias G, Ciliberto G & Poli V (1996) Correlations between IL-6 and arthritis: a genetic approach. The 1996 Meeting on Mouse Molecular Genetics, Cold Spring Harbour, New York, USA, August 1996.
155. Kollias G, Akassoglou K, Alexopoulou L, Douni E, Haralambous S, Hill S, Kassiotis G, Kontoyiannis D, Pasparakis M, Plows D & Probert L . The use of transgenic and knockout mice for the analysis of the immune and inflammatory activities of TNFa. Nato ASI: Vaccine Design: The Role of Cytokine Networks, Cape Sounion, Greece, 24 June – 5 July 1996 (invited speaker, G Kollias).
156. Akassoglou K, Probert L & Kollias G (1996) A role for astrocyte-specific transmembrane TNF in the triggering of inflammation, demyelination and neuronal degeneration in the CNS of transgenic mice. The 1996 FASEB Summer Research Conference on Neural Immune Interactions in Injury and Disease: Molecules and

Mechanisms, Copper Mountain, Colorado, July 1996 (selected for oral presentation, K Akassoglou).

157. Probert L, Kassiotis G, Akassoglou K, Pasparakis M, Alexopoulou L & Kollias G (1996) Transgenic animal models of TNF-mediated CNS pathology. Sixth International TNF Congress, Rhodes, May 1996 (invited speaker, L Probert). *Eur. Cyt. Netw*. 7 (2): 246.
158. Kollias G, Akassoglou K, Alexopoulou L, Douni E, Haralambous S, Kontoyiannis D, Pasparakis M, Plows D & Probert L (1996) Disease pathogenesis and immune regulation in TNF transgenic and knock-out mice. Sixth International TNF Congress, Rhodes, May 1996 (invited speaker, G Kollias). *Eur. Cyt. Netw.* 7 (2): .
159. Kassiotis G, Matsoukas J, Kollias G & Probert L (1996) T-cell autoreactivity in a transgenic model of TNF-triggered CNS inflammatory demyelinating disease. Sixth International TNF Congress, Rhodes, May 1996 (poster presentation, G Kassiotis). *Eur. Cyt. Netw*. 7 (2): 261.
160. Haralambous S, Probert L, Mastrangelo M, Kollias G & Molony L (1996) Adhesion molecule blockade modulates the development of TNF-triggered arthritis in transgenic mice. Sixth International TNF Congress, Rhodes, May 1996 (poster presentation, S Haralambous). *Eur. Cyt. Netw*. 7 (2): 293.
161. Cope A, Liblau R, Congia M, Yang X-D, Schreiber R, Probert L, Kollias G & McDevitt HO (1996). Tumour necrosis factor (TNF) alpha: regulator of T cell responses in health and disease. Sixth International TNF Congress, Rhodes, May 1996 (selected for oral presentation, A Cope). *Eur. Cyt. Netw*. 7 (2): 253.
162. Aloe L, Probert L, Kollias G, Fiore M, Akassoglou K & Angelucci F (1996). Nerve growth factor level in the brain of transgenic mice expressing tumor necrosis factor is differentially affected. Sixth International TNF Congress, Rhodes, May 1996 (poster presentation, M Fiore). *Eur. Cyt. Netw*. 7 (2): 229.
163. Akassoglou K, Probert L, Kontogeorgos G & Kollias G (1996). Astrocyte, but not neuron-specific, expression of transmembrane TNF triggers CNS inflammation, demyelination and neuronal degeneration in transgenic mice. Sixth International TNF Congress, Rhodes, May 1996 (poster presentation, K Akassoglou). *Eur. Cyt. Netw*. 7 (2): 249.
164. Akassoglou K, Probert L, Kontogiorgos G & Kollias G (1996) Astrocyte-specific TNF induces inflammatory demyelination and neurodegeneration in the CNS of transgenic mice. Fifth Hellenic Conference of Pathological Anatomy, Ioannina, Hellas, May 1996 (selected for oral presentation, K Akassoglou). KA received the DODONI Young Investigator Award.
165. Probert L, Kassiotis G, Akassoglou K & Kollias G (1996) TNF deregulation in the CNS of transgenic mice triggers neuro-inflammatory demyelinating disease with autoimmune characteristics. BIOMED-Concerted Action Symposium: Cytokines in the Brain: Neuropathological Aspects, St-Jean-de-Luz, France, April 25-28, 1996 (poster presentation, L Probert).
166. Probert L, Akassoglou K, Kassiotis G & Kollias G (1995) Transgenic animal models of human neurodegenerative diseases: aiding drug design. Biomed Workshop - Amino Acids, Peptides and Proteins/Drug Discovery and Design, Patras, Greece, November 1995 (invited speaker, L Probert).
167. Kollias G, Akassoglou K, Kassiotis G & Probert L (1995) TNF in CNS Pathology: Lessons from transgenic mice. The Greek Neurobiology Society, Metsovo, Greece, November 1995 (invited speaker, G Kollias).
168. Kollias G, Akassoglou K, Alexopoulou L, Georgopoulos S, Haralambous S, Plows D & Probert L (1995) Dissection of the pathologies induced by transmembrane and wild-type TNF in transgenic mice. Third Annual Conference of the International Cytokine Society, Harrogate, UK, September 1995 (invited speaker, G Kollias). Cytokine 7 (6): 666.
169. Probert L, Akassoglou K, Pasparakis M, Kontogeorgos G & Kollias G (1995) Overexpression of TNF in the CNS of transgenic mice induces chronic inflammatory

neurological disease. Advances in the understanding and treatment of Multiple Sclerosis, Cambridge, MA, USA, May 1995 (poster presentation, L Probert).

170. Kollias G, Alexopoulou L, Georgopoulos S, Plows D & Probert L (1995) Transgenic analyses on the role of TNF and IL-1 in arthritis. Third International Symposium on Immunotherapy of Rheumatic Diseases, Cyprus, May 1995 (invited speaker, G Kollias).
171. Akassoglou K (1995) Constitutive expression of TNF in the CNS of transgenic mice induces chronic inflammatory neurologic disease. Philippe Laudat Conferences INSERM "Demyelination and Remyelination", Aix-Les-Bains, France, September 1995 (selected oral presentation, K Akassoglou).
172. Alleva E, Fiore M, Probert L, Kollias G, Aloe L (1994). Modificazioni comportamentali e sensibilita al dolore in topi transgenici per il tumor necrosis factor (TNF-alpha). Seminars Department Experimental & Bichemical Science of the University of Rome Tor Vergata. March 1995.
173. Aloe L, Kollias G, Probert L, Bracci-Laudiero L, Tirassa P, Spillantini MG, Levi-Montalcini R (1994). Increased NGF level in the synovia of transgenic arthritic mice.
174. Probert L, Akassoglou K & Kollias G (1994) Tumour necrosis factor expression in the CNS of transgenic mice induces neurological disease. Fourth International Congress of Neuroimmunology, Amsterdam, October 1994 (selected for oral presentation, K Akassoglou). *J. Neuroimmunol*. 54.
175. Georgopoulos S, Probert L, Kollias G (1994) Tumor necrosis factor: a specific trigger in arthritis. The 26th Meeting of the German Rheumatology Society, Berlin, Germany, September 1994 (invited speaker, G Kollias). *Zeitschrift fur Rheumatologie* 53 suppl. 1: 91.
176. Probert L & Kollias G (1994) Overexpression of TNF in the brain of transgenic mice induces neurologic disease. Faseb Summer Research Conference 'Interactions of the nervous and immune systems', Colorado, July 1994 (poster presentation, L Probert).
177. Probert L & Kollias G (1994). TNF expression in the CNS of transgenic mice induces neurologic disease. Fifth International TNF Congress, Monterey, California, May 1994 (poster presentation, L Probert). *European Cytokine Network* 5: 176.
178. Kollias G, Dodou E, Douni E, Georgopoulos S, Harami P, Pasparakis M & Probert L (1994) Modeling arthritis in transgenic mice. Fourth International TNF Congress, Monterey, California, May 1994 (invited speaker, G Kollias). *European Cytokine Network* 5: 176.
179. Kollias G, Alexopoulou L, Douni E, Georgopoulos S, Pasparakis M & Probert L (1993). Modelling arthritis in transgenic mice. Sixth French Congress of Rheumatology, November 1993 (oral presentation, G Kollias).
180. Kollias G, Douni E, Georgopoulos S, Pasparakis M & Probert L (1993). Analysis of tumour necrosis factor biology in transgenic mice. Keystone Symposium, Cytokines and Cytokine Receptors: From Cloning to the Clinic. Keystone, Colorado, February 1993 (selected for oral presentation, G Kollias). *J. Cellular Biochemistry* Abstract Suppl. 17B: 92.
181. Kollias G, Dodou E, Douni E, Georgopoulos S, Harami P, Pasparakis M & Probert L (1993) Modeling arthritis in transgenic mice. Thirteenth European Workshop for Rheumatology Research, Brighton, UK, January 1993 (invited speaker, G Kollias). *Clinical Rheumatology* 12: 2.
182. Kollias G, Dodou E, Douni E, Georgopoulos S, Harami P, Pasparakis M & Probert L (1992). Transgenic approaches in the study of tumour necrosis factor biology. The 8th Annual Symposium on Biotechnology, 'The Cytokine System in Health and Disease', London, UK, December 1992 (oral presentation, G Kollias).
183. Probert L, Dodou E, Douni E, Georgopoulos S, Pasparakis M & Kollias G (1992) Transgenic models of human tumour necrosis factor mediated disease. The 1992 Meeting on Mouse Molecular Genetics, Cold Spring Harbor Laboratory, NY, August 1992 (poster presentation, L Probert), Abstract book p166.

184. Kollias G, Corbella P, Dodou E, Georgopoulos S, Hislop S, Kaslaris E, Kioussis D, Pasparakis M & Probert L (1992). Transgenic models of tumour necrosis factor mediated disease. Fourth International Conference on TNF and Related Cytokines, Veldhoven, The Netherlands, May 1992 (invited speaker, G Kollias).
185. Kollias G, Cazlaris H, Georgopoulos S, Keffer J, Probert L (1992). TNF-mediated disease in transgenic mice: a genetic model of arthritis. Keystone Symposia, Taos, February 1992.
186. Probert L, Keffer J, Cazlaris H, Georgopoulos S & Kollias G (1991). TNF-mediated disease in transgenic mice: a genetic model of arthritis. Third International Workshop on Cytokines, Stresa, Italy, November 10-14, 1991 (poster presentation, L Probert).
187. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D & Kollias G (1991). Transgenic mice expressing human TNF: a genetic model of arthritis. The F Jacob Conference, IMBB, Crete, October 1991 (poster presentation, H Cazlaris).
188. Probert L, Keffer J, Georgopoulos S, Cazlaris H, Patsavoudi E, Lymberi P, Kaslaris E, Kioussis D & Kollias G (1991). T cell-targeted TNF expression in transgenic mice: local and systemic modes of action. The F. Jacob Conference, IMBB, Crete, October 1991 (poster presentation, S Georgopoulos).
189. Kollias G, Cazlaris H, Georgopoulos S, Keffer J & Probert L (1991). TNF-mediated disease in transgenic mice: a genetic model of arthritis. The 1991 Meeting on Mouse Molecular Genetics, EMBL, Heidelberg, August 1991 (poster presentation, G Kollias), Abstract book p55.
190. Kollias G, Cazlaris H, Kaslaris E, Keffer J, Patsavoudi E, Probert L (1990). Analysis of human tumour necrosis factor gene expression and biological function in transgenic mice. Third International Conference on Tumour Necrosis Factor and Related Cytokines, Makuhari, Japan, November 1990.
191. Kollias G, Cazlaris H, Kaslaris E, Keffer J, Probert L (1990). Analysis of human tumour necrosis factor gene expression and biological function in transgenic mice. Reunion of Directors of Reseau International of the Pasteur Institutes and Associated Institutes, Athens, Greece, September 1990 (oral presentation, G Kollias).
192. Probert L (1989). Abnormalities of the enteric neuropeptide system in inflammatory bowel disease. International Meeting on IBD, Athens, April 1989 (invited speaker). *Scand. J. Gastroenterology* 24 suppl. 158: 40-41.
193. Hanley MR, Probert L, Spillantini MG & Too HP (1988). High performance liquid chromatography of naturally occurring tachykinins and their enzymatic breakdown products. Seventh General Meeting of the European Society for Neurochemistry, June 1988 (poster presentation, MR Hanley).
194. Spillantini MG, Probert L, Fanciullacci M, Hanley MR & Sicuteri F (1988). Metabolism of sensory neuropeptides. Research on Sensory Neuropeptides in Italy: An Update", Florence, May 1988 (oral presentation, MG Spillantini).
195. Hanley MR, Jessell TM, Jones C, Macallan D, Probert L, Too HP, Wakelam MJO & Zamboni G (1984). Peptide receptors in the brain and periphery. Fourteenth Congress of the International Neuropharmacology, New York, USA, 1984 (oral presentation, MR Hanley). *Clinical Neuropharmacology* 7 suppl. 1: 48-49.
196. Polak JM, Probert L & De Mey J (1983). Ultrastructural localisation of VIP in the peripheral nervous system using gold labelling procedures. First International Symposium of VIP and Related Peptides, Brussels, September 1983 (oral presentation, JM Polak).
197. Probert L, De Mey J, Bloom SR & Polak JM (1983). The ultrastructural localisation of neuropeptide Y (NPY)-immunoreactivity within the gut and its association with sympathetic nerves. The 146th Meeting of the Pathological Society of Great Britain & Ireland, Edinburgh, Scotland. July 1983 (selected for oral presentation, L Probert). *J. Pathology* 139: 499.

198. Varndell IM, Probert L, Tapia FJ, Lackie PM, De Mey J & Polak JM (1983). Relevance of immunogold staining procedures for the analysis of endocrine control. The European Winter Conference on Brain Research, Les Arcs, France, March 1983 (oral presentation, I Varndell).
199. Ferri G-L, Facer P, Probert L, Bishop AE, Cocchia D, Michetti F, Vezzadini P, Labo G, Marangos PJ & Polak JM (1982). Diagnostic endoscopy for alterations in the enteric nervous system using a protein marker for neurons and glia. Italian Society for Digestive Endoscopy, Catania, Sicily, December 1982 (oral presentation, G-L Ferri).
200. Ferri G-L, Facer P, Probert L, Bishop AE, Cocchia D, Michetti F, Vezzadini P, Marangos PJ & Polak JM (1982). The use of enzyme markers for the demonstration of the neuron and glial components of the human enteric nervous system. Convention of Italian Gastroenterology Society, Genova, Italy, November 1982 (oral presentation, G-L Ferri).
201. Bloom SR, Gu J, Probert L, Kazi I, Mina S, McGregor GP, O`Shaughnessy DJ & Polak JM (1982). Peptidergic innervation of the human male genital tract. The Medical Research Society Meeting, Edinburgh, July 1982 (oral presentation, S Bloom).
202. Varndell IM, Tapia FJ, Probert L, De Mey J & Polak JM (1982). Double immunogold staining procedures for the ultrastructural localisation of regulatory peptides in health and disease. The 145th Meeting of the Pathological Society of Great Britain & Ireland, Sheffield, UK, July 1982 (poster presentation, I Varndell). *J. Pathology* (1983) 139: 486.
203. Sabate IM, Stephenson C, Bishop AE, Probert L, Cole GA, Hodson NP, Edwards BA, Yeats J, Bloom SR & Polak JM (1982). Pathological changes in the regulatory peptides of the gut in equine grass sickness. The 145th Meeting of the Pathological Society of Great Britain & Ireland, Sheffield, UK, July 1982 (poster presentation, J Polak). *J. Pathology* (1983) 139: 484.
204. Probert L, Facer P, De Mey J & Polak JM (1982). Ultrastructural heterogeneity of p-type nerves due to peptide content. The 145th Meeting of the Pathological Society of Great Britain & Ireland, Sheffield, UK, July 1982 (poster presentation, J Polak). *J. Pathology* (1983) 139: 499.
205. Tapia FJ, Varndell IM, Probert L, Gosselin EJ, De Mey J & Polak JM (1982). A double immunogold staining method for the simultaneous ultrastructural localisation of regulatory peptides. Fourth International Symposium on Gastrointestinal Hormones, Stockholm, Sweden, June 1982 (oral presentation, J Polak). *Scand. J. Gastroenterology* 17: suppl. 78.
206. Polak JM, Bishop AE, Cole GA, Probert L, Stephenson C, Sabate MI, Hodson NP, Edwards BA, Yeats J & Bloom SR (1982). Gut peptides in equine grass sickness. Fourth International Symposium on Gastrointestinal Hormones, Stockholm, Sweden, June 1982 (poster presentation, J Polak). *Scand. J. Gastroenterology* 17 suppl. 78: 505.
207. Ferri G-L, Adrian TE, Ghatei MA, O`Shaughnessy D, Probert L, Lee YC, McGregor S, Sarson D, Polak JM & Bloom SR (1982). Relative distribution and tissue localisation of regulatory peptides in separated layers from the human bowel. Fourth International Symposium on Gastrointestinal Hormones, Stockholm, Sweden, June 1982 (poster presentation, J Polak). *Scand. J. Gastroenterology* 17 suppl. 78: 505.
208. Polak JM, Varndell IM, Probert L, Tapia F, De Mey J & Bloom SR (1982). Immunogold staining for the ultrastructural localisation of regulatory peptides in the gut. Annual Meeting of the American Gastoenterology Association, May 1982 (oral presentation, J Polak). *Gastroenterology* 82: 1151.
209. Polak JM, Ferri G-L, Probert L, Bishop AE, Cocchia D, Michetti F, Marangos PJ & Bloom SR (1982). Delineation of the entire enteric nervous system by the use of antibodies to brain proteins. Annual Meeting of the American Gastoenterology Association, May 1982 (oral presentation, J Polak). *Gastroenterology* 82: 1150.
210. Tapia FJ, Varndell IM, Probert L, Gosselin EJ, De Mey J & Polak JM (1982). Immunogold staining methods (IGS) for the simultaneous ultrastructural localisation of

molecular form variants of pancreatic hormones. The Annual Histochemistry Meeting, Oxford, UK, April, 1982 (oral presentation, F Tapia). *Proc. Royal Micr. Soc.* 17: 133.

211. Ferri G-L, Probert L, Michetti F, Cocchia D & Polak JM (1982). A newly discovered brain protein in the non-neuronal components of the gut innervation. The British Society of Gastroenterology, Norwich, UK, March 1982 (poster presentation, G-L Ferri). *Gut* 23: A433.
212. Varndell IM, Tapia FJ, Buchan AMJ, Probert L, De Mey J & Polak JM (1982). Immunogold staining procedure for the localisation of regulatory peptides in health and disease. The 144th Meeting of the Pathological Society of Great Britain & Ireland, January 1982 (poster presentation, I Varndell). *J. Pathology* 138: 87.
213. Terenghi G, Polak JM, McGregor GP, Probert L, Butler JM, Cole DF & Bloom SR (1982). Mapping and quantification of substance P and VIP immunoreactivity in the uvea. The 144th Meeting of the Pathological Society of Great Britain & Ireland, January 1982 (poster presentation, G Terenghi). *J. Pathology* 138: 94.
214. Ferri G-L, Cocchia D, Michetti F, Probert L, Marangos PJ & Polak JM (1982). The S-100 brain protein in the human enteric nervous system. The 144th Meeting of the Pathological Society of Great Britain & Ireland, January 1982 (poster presentation, G-L Ferri). *J. Pathology* 138: 68.
215. Varndell IM, Probert L, Tapia FJ, Buchan AMJ, Gu J, De Mey J, Bloom SR & Polak JM (1982). Immunogold staining method for the localisation of peptide neurotransmitters and hormones at the light- and electron-immunocytochemical levels. Third Winter Conference on Neuropeptides, Colorado, January 1982 (oral presentation, I Varndell).
216. Ferri G-L, Polak JM, Adrian TE, Buchan AMJ, Probert L, Ghatei MA, Lee YC & Bloom SR (1982). Layer separation of the human bowel for the study of regulatory peptides. *Regulatory Peptides* 3: 70.
217. Ferri G-L, Harris A, Probert L, Buchan AMJ, Bloom SR & Polak JM (1981). Cell and layer separation from the gut wall for the study of the regulatory peptide system in man. *Italian J. Gastroenterology* 13: 273.
218. Varndell IM, Probert L, Tapia FJ, Buchan AMJ, Gu J, De Mey J & Polak JM (1981). Immunogold staining procedure for the localisation of regulatory peptides at the light and electron microscopical levels. The National Scientific Meeting of the Bayliss and Starling Society, London, December 1981 (poster presentation, I Varndell). *Regulatory Peptides* (1982) 3: 85.
219. Bishop AE, Cole GA, Probert L, Hodson NP, Bloom SR & Polak JM (1981). Marked changes in the regulatory peptide system of the bowel in equine grass sickness. The National Scientific Meeting of the Bayliss and Starling Society, London, December 1981 (poster presentation, A Bishop). *Regulatory Peptides* (1982) 3: 65.
220. Polak JM, Buchan AMJ, Probert L, Tapia FJ, Varndell IM, De Mey J & Bloom SR (1981). Electron microscopical features of peripheral endocrine cells and autonomic nerves storing regulatory peptides. Eighth European Congress of Pathology, Helsinki, Finland, September 1981 (oral presentation, J Polak).
221. Probert L, De Mey J, Ferri G-L & Polak JM (1981). Substance P and VIP are present in distinct subpopulations of p-type enteric neurons. The 143rd Meeting of the Pathological Society of Great Britain & Ireland, Dundee, Scotland, July 1981 (poster presentation, L Probert). *J. Pathology* (1982) 137: 69.
222. Ferri G-L, Harris A, Probert L, Buchan AMJ, Bloom SR, Polak JM (1981). Separation of the cellular mucosa of the intestine for the study of regulatory peptides in the human. The Annual Meeting of the Italian Society of Gastroenterologists, Bologna, Italy, July 1981 (oral presentation, G-L Ferri).
223. Probert L, De Mey J & Polak JM (1981). Peptidergic nerves are distinguishable by the appearance and size of their large granular secretory vesicles. The British Society for Gastroenterology, June 1981 (poster presentation, L Probert). *Gut* 22: A898.

224. Ferri G-L, Harris A, Probert L, Buchan AMJ, Marangos PJ, Adrian TE, Ghatei MA, Bloom SR & Polak JM (1981). Layer separation from human gut for the study of regulatory peptides in the neuroendocrine system (NES). The British Society for Gastroenterology, June 1981 (poster presentation, G-L Ferri). *Gut* 22: A898.
225. Polak JM & Probert L (1981). Substance P is present in a distinct subpopulation of p-type enteric neurons. The Annual Meeting of the American Gastoenterology ssociation, May 1981 (oral presentation, J Polak). *Gastroenterology* 80: 1253.
226. Probert L & Polak JM (1980). Ultrastructural localisation of substance P in the innervation of the gut wall. The 161st Meeting of the Society for Endocrinology, London, November 1980 (poster presentation, L Probert).
227. Probert L & Polak JM (1980). Immunoelectroncytochemistry of substance P. Presented at the Meeting of Royal Society of Medicine, (Pathology Section), London, October 1980 (oral presentation, L Probert).
228. Probert L (1980). Ultrastructure of the gut innervation. Presented at the Postgraduate Histopathology Seminars, Mini-Symposium on Distribution and Tissue Localisation of Regulatory Peptides of the Gut, Royal Postgraduate Medical School, October 1980 (oral presentation, L Probert).